

2008年報

ANNUAL REPORT



香港防癌會

THE HONG KONG ANTI-CANCER SOCIETY



From Vision ... To Mission...

The Hong Kong Anti-Cancer Society
Jockey Club Cancer Rehabilitation Centre



香港社會服務聯會
The Hong Kong Council of Social Service



香港公益金
THE COMMUNITY CHEST

Contents 目錄

1.	Presidential Address by Dr. York Y.N. Chow, SBS, JP, Secretary for Food and Health 會長食物及衛生局局長周一嶽醫生致辭全文	2
2.	Chairman's Report 主席報告	5
3.	Reports from various Committees and Subcommittees 各委員會之報告	
i)	Jockey Club Cancer Rehabilitation Centre 賽馬會癌症康復中心	7
ii)	Administration and Finance Subcommittee 行政及財務委員會	15
iii)	Betterment Fund for Cancer Patients Subcommittee 『改善癌病人生活基金』委員會	20
iv)	Cancer Education Subcommittee and Cancer Detection & Prevention Subcommittee 癌症教育委員會和癌症探測及預防委員會	26
v)	Cancer Research Subcommittee 癌症研究委員會	35
vi)	Fundraising and Publicity Subcommittee 籌募及推廣委員會	48
4.	Acknowledgement 鳴謝	51
5.	Honorary Treasurer's Report 義務司庫報告	54
6.	Financial Report 2007/08 財務報告2007/08	56

The 45th Annual General Meeting of The Hong Kong Anti-Cancer Society,

8 December 2008 Speech by Dr York Chow, SBS, JP, Secretary for Food and Health

二零零八年十二月八日

香港防癌會第四十五屆周年大會

食物及衛生局局長周一嶽醫生致辭全文

Dr Ko, distinguished guests, fellow Committee Members, ladies and gentlemen,

It is my pleasure to join you today for the 45th Annual General Meeting of The Hong Kong Anti-Cancer Society, to celebrate the achievements of the Society over the past year and to strategize its future plan.

When the Society was established in the 1960s, cancer was often seen as a dreadful disease with very few available treatment options. Thanks to the strenuous efforts by generations of medical researchers and healthcare professionals, various breakthroughs in cancer research have been achieved and the management of cancer has also been largely improved over the past four decades. Nevertheless, cancer still remains a major public health threat in Hong Kong.

Since the 1960s, cancer has been the number one killer disease in Hong Kong and the number of cancer deaths and new cancer cases has risen steadily. In 2005, about 23,000 cancer new cases were registered in Hong Kong. The most common new cases of cancer in men are lung cancer, colorectal cancer and liver cancer; and the list for women is breast cancer, colorectal cancer and lung cancer. In 2007, cancer claimed over 12,000 lives in Hong Kong, accounting for about one third of the total deaths of the population.

While the Government will continue to spare no efforts to fight against cancer diseases, aging population and lifestyle changes pose huge challenges to this task. To rise to the challenges, we need strategic planning and coordinated implementation. Our strategy is rigorous surveillance, aggressive prevention and best treatment.

We must know our enemy before we can win a battle. Government has strengthened our surveillance of both cancer cases and behavioural risk factors. Since 2005, we have reinvigorated the Cancer Registry set up under the Hospital Authority to capture data in a more timely and extensive manner and to monitor

高（永文）醫生、各位嘉賓、各位會員、各位先生、女士：

今天我很高興能夠出席香港防癌會第四十五屆周年大會，與大家聚首一堂，慶祝防癌會在過去一年取得的佳績，並為未來發展制訂策略方針。

香港防癌會於上世紀六十年代成立，當時癌症的治療方法少之又少，人們往往談癌色變。憑著一代又一代醫療研究人員和專業醫護人員鍥而不捨的努力，在過去四十年間，癌症研究屢有突破，而對癌症的控制亦有長足的改善。不過，時至今日，癌症仍然對本港市民的健康構成重大威脅。

自上世紀六十年代以來，癌症一直是本港頭號殺手，而因癌症而死亡的人數和新增癌症個案均不斷上升。二零零五年，本港約有23,000宗癌症新增個案。男性最常見的癌症新增個案分別是肺癌、大腸癌及肝癌；女性最常見的新增個案則分別是乳癌、大腸癌及肺癌。二零零七年，本港約有12,000人死於癌症，佔總死亡人口三分之一。

政府誠然會繼續不遺餘力對抗癌症，但人口老化和生活方式的轉變，卻為這項任務帶來重大考驗。要克服面前的種種挑戰，我們需要作出策略性規劃，以及在執行措施時作出協調。我們的總體策略是進行嚴格的監察、積極的預防和最佳的治療。

所謂知己知彼，百戰百勝，政府已致力加強監察癌症個案和行為風險因素。自二零零五年起，我們已強化醫院管理局轄下的癌症資料中心，以便更及時和廣泛地掌握癌症數據，並更密切地監察癌症的發病率

more closely incidence and mortality rates. Registry data are stimulating cancer awareness and are being used by hospitals or NGOs to plan services and resources as well as to facilitate cancer prevention and control. We also set up in 2005 a Behavioural Risk Factor Surveillance System under the Department of Health to tap on the trend of different behavioural factors associated with various diseases including cancers. Through the Surveillance System, telephone survey is conducted every year to collect information on health-related behaviours of the adult population, including those closely linked to cancers such as smoking and lack of exercise. The survey also covers information on cervical cancer screening practices. This Surveillance provides useful data for Government to plan and evaluate health promotion and cancer prevention programmes.

Cancers can kill. So it is important to focus on prevention. We have an inter-departmental and cross-disciplinary Cancer Co-ordinating Committee under my chairmanship to strategize the overall prevention and control of cancers for Hong Kong. Our preventive strategy focuses on promoting healthy lifestyle and minimizing factors conducive to cancers such as smoking, alcohol misuse, physical inactivity, unhealthy diet and excess weight. The Department of Health has recently launched the Strategic Framework for Prevention and Control of Non-communicable diseases (NCDs) to tackle head-on NCDs including cancers.

We will be relentless in seeing through implementation of this Strategic Framework. For this, I have set up a steering committee putting together the best brains in the field, both inside and outside Government, to oversee development and progress of the implementation of the Framework. Expert working groups will be formed to advise and inspire actions, draw up targets and forge partnership between Government and various sectors of the community.

In the meantime, we are strengthening existing services and programmes for cancer prevention. Notably, we will continue with vigorous promotion of a smoke-free environment and culture in Hong Kong. By July 2009, our smoking ban will extend to facilities like bars, massage parlours and mahjong premises.

On the treatment front, I am pleased to report that the Hospital Authority has undertaken steps to strengthen the capacity of its cancer services. Apart from the cancer centre of Princess Margaret Hospital that opened last year, Hospital Authority will also set up an integrated breast centre and an oncology outpatient clinic in the United Christian Hospital in Kowloon East Cluster in 2008-09 to provide one-stop, multidisciplinary services to breast cancer patients. It is estimated that an additional 1,800 breast cancer patients will be benefited each year.

和死亡率。該中心的數據有助提高對癌症的認識，而各醫院及非政府機構正利用這些數據規劃其服務和資源，以及促進預防和控制癌症的工作。衛生署亦在二零零五年建立行為風險因素監測系統，目的是了解與各種疾病(包括癌症)有關的不同行為因素的趨勢。該監測系統每年通過電話調查，收集成年人口各種與健康有關的行為模式資料，包括與癌症息息相關的行為風險因素，例如吸煙和缺少運動、以及接受子宮頸癌普查的情況等等。這項調查提供了重要的資料，有助政府制訂和評估促進健康和預防癌症的計劃。

癌症足以致命，因此我們必須着重於預防癌症和及早治療的工作。現時我們已設有一個跨部門和跨專業的癌症事務專責委員會，由我本人擔任主席，負責為香港制訂全面的癌症預防和控制策略。我們預防策略注重提倡健康生活方式，針對吸煙、濫用酒精、缺乏體能活動、不良飲食習慣和肥胖等誘發癌症的因素。衛生署最近推出非傳染病防控策略框架，目的是全面防抗包括癌症在內的各種非傳染病。

我們會竭盡所能，確保這個策略框架得到落實。為此，我已成立一個督導委員會，匯聚公私營界別的專才，共同監督策略框架的發展和整體推行進度。此外我們並會成立專家工作小組，提供意見，訂立目標，以及推動政府和社會各界建立伙伴關係。

與此同時，我們亦不斷加強現時的癌症預防服務和計劃，特別是繼續在香港大力推廣無煙環境和文化。到了二零零九年七月，我們的禁煙規定將會擴展至酒吧、按摩浴室和麻將處所等措施。

在治療方面，我很高興向各位報告，醫院管理局已採取措施提升其診治癌症服務量。除了去年啟用的瑪嘉烈醫院癌症中心外，醫院管理局亦會在二零零八至零九年度於九龍東聯網的基督教聯合醫院內設立綜合乳科中心和腫瘤科門診，為乳癌患者提供一站式及跨專業服務，預計每年約有額外1,800名乳癌患者受惠。

While expanding the capacity of cancer services, we are equally committed to the quality of care. To improve clinical care for cancer patients, the Hospital Authority will enhance provision of new cancer drugs in all its oncology centres in 2008-09. It is estimated that around 400 patients will be provided with new cancer drug. In addition to treatment services, HA has also been providing rehabilitation service and palliative care to cancer patients through a community approach. Community nurses will pay home visits to patients to follow-up on their treatment in patients' familiar environment, providing services ranging from pain alleviation to emotional counseling. All of the above add up to form the holistic support we render to cancer patients.

Partnership among the Government, private sector and the community is the key to successful cancer prevention and control. I am particularly glad to see that The Hong Kong Anti-Cancer Society, being one of the Government's leading allies in the fight against cancer, has dedicated over the past 40 years to promoting, coordinating and participating in anti-cancer activities with commitment and distinction. This year, the Society has conducted several press conferences on prevention of skin cancer and cervical cancer. As for services for cancer patients, the Society has organized a variety of activities such as festive celebrations and support groups for home-based cancer patients through its out-reaching recreational programmes. The opening of The Hong Kong Anti-Cancer Society Jockey Club Cancer Rehabilitation Centre, which is situated in the re-developed site of the former Nam Long Hospital, further equips the Society with more extensive facilities and human resources to deliver rehabilitation services in the fight against cancer.

I wish the Society continued success in its quest for better health of Hong Kong people. Thank you.

在擴大癌症服務量的同時，我們亦同樣重視服務質素。為改善癌症病人的臨牀護理，醫院管理局於二零零八至零九年度，在轄下所有腫瘤科中心增加提供新癌症藥物。預計約有400名病人會獲提供新癌症藥物。除治療服務外，醫管局亦一直透過社區為本的方式，為癌症病人提供康復服務和紓緩治療。社康護士會對病人進行家訪，以便在病人熟悉的環境中跟進他們的治療，並提供各種服務包括幫助病人紓緩痛楚，以及為他們進行情緒輔導。以上種種服務互相配合，為癌症病人提供全面的支持。

為了有效預防和控制癌症，政府、私營機構和社會各界需要攜手合作。我特別感到欣慰的是，香港防癌會在抗癌工作上一直與政府並肩作戰，過去四十年來積極推廣、統籌和參與各項抗癌活動，成績有目共睹。今年，防癌會舉辦了多次有關預防皮膚癌和子宮頸癌的記者會。至於為癌症病人提供的服務，防癌會透過外展康樂計劃為家居癌症病人舉辦了多類活動，例如節日慶祝和支援小組等。由前南朗醫院改建而成的香港防癌會賽馬會癌症康復中心亦已經啟用，讓防癌會擁有更完備的設施和人力資源，及以康復服務的理念及模式，進一步推展抗癌的工作。

香港防癌會致力促進香港市民的健康，並取得卓越成果。祝願防癌會再接再厲，續創佳績。謝謝各位。

Chairman's Report 主席報告



Ko Wing Man
高永文

It gives me great pleasure in presenting the Annual Report of The Hong Kong Anti-Cancer Society (HKACS) for the 12-month period from 1 October 2007 to 30 September 2008 on (1) Organisation; (2) Jockey Club Cancer Rehabilitation Centre; (3) Administration & Finance; (4) Betterment for Cancer Patients; (5) Cancer Education; (6) Cancer Detection and Prevention; (7) Cancer Research and (8) Fundraising & Publicity.

本人欣然在此向各位匯報本會自2007年10月1日至2008年9月30日止12個月期間的各項工作，包括(1)本會組織、(2)賽馬會癌症康復中心、(3)行政及財務、(4)改善癌病人生活、(5)癌症教育、(6)癌症探測及預防、(7)癌症研究和(8)籌募及推廣。



香港公益金

THE COMMUNITY CHEST

Organisation 本會組織

The Hong Kong Anti-Cancer Society is a member agency of the Community Chest of Hong Kong and the Hong Kong Council of Social Service. All funds allocated by the Chest each year are used to meet part of the operating expenses of the Society's Administration, Cancer Education and the Recreational & Diversional Therapy Unit. The other expenses are funded by public donations and sponsorship.

香港防癌會是香港公益金資助的機構及香港社會服務聯會的會員。每年公益金的撥款均全數用於資助本會行政、癌症教育及康樂治療小組的部份運作開支。本會的其它活動經費，則全賴公眾捐獻及贊助。

Membership of the Executive Committee 2007/08

2007/08 年度執行委員會委員名單

President 會長:	Secretary for Food and Health Dr. York Y.N. CHOW, SBS, JP	食物及衛生局局長 周一嶽醫生, SBS, JP
Hon. Vice-President 名譽副會長:	Ms. Ina CHAN Un-chan Mrs. Mariana CHENG, BBS, JP Mrs. Nina LAM Mrs. Kathryn LOUEY, SBS	陳婉珍女士 鄭曹志安女士, BBS, JP 林李婉冰女士 雷羅慧洪女士, SBS
Hon. Advisor 名譽顧問:	Mr. John WONG	黃培傑先生
Chairman 主席:	Dr. KO Wing-man	高永文醫生
Vice-Chairman 副主席:	Dr. POON Yeuk-foo	潘若芙醫生
Hon. Secretary 義務秘書:	Mr. Davie AU-YEUNG	歐陽贊邦先生
Hon. Treasurer 義務司庫:	Mr. Edwin CHIU Ngar-wing	趙雅穎先生
Members 委員:	Dr. Hubert CHAN Mrs. Patricia CHU YEUNG Pak-yu, BBS Dr. Daniel CHUA Tsin-tien Dr. LAW Chun-key Dr. Anne LEE Wing-mui Dr. Pamela LEUNG Mrs. Selina LO Ms. Alisha MA Hsiao-hung Dr. TUNG Yuk Dr. WANG Ming-chun, Elizabeth, SBS Mrs. Agnes WONG Dr. Anthony YING	陳重義博士 朱楊珀瑜女士, BBS 蔡清洙醫生 羅振基醫生 李詠梅醫生 梁明娟醫生 羅黃少眉女士 馬奕彤女士 董煜醫生 汪明荃博士, SBS 黃馮玉棠女士 應志浩醫生
Hon. Legal Advisor 義務法律顧問:	Mr. SHUM Man-kwong	岑文光先生
Hon. Auditor 義務核數師:	Chang Leung Hui & Li C.P.A. Ltd. Certified Public Accountants	岑張梁許李會計師 事務所有限公司

Jockey Club Cancer Rehabilitation Centre 賽馬會癌症康復中心

A) Project Management 項目管理

The Project Management Committee continued its intensive efforts in managing the team of project consultants and contractor(s), to drive the addition and alteration works at the Jockey Club Cancer Rehabilitation Centre to its completion. The premises was handed back to The Hong Kong Anti-Cancer Society in late April 2008 with a small list of outstanding items. The difficulties resulted from some unexpected structural problems found after renovation commencement were overcome. The Society was extremely grateful to The Hong Kong Jockey Club Charities Trust's supplementary grant of \$12.87M to cover budget shortfall for the same reason. The total grant amounted to \$109.23M.

項目管理委員會繼續與工程顧問及承辦商緊密合作，務求賽馬會癌症康復中心的擴建及改建工程能得以完成。2008年4月下旬承辦商交回上述物業予香港防癌會，工程大致已完竣，惟有小部份工程仍需跟進。雖然在修繕開始後曾發生一些難以意料的結構性問題，但最終仍得以迎刃而解。本會非常感謝香港賽馬會慈善信託基金慷慨額外資助港幣1,287萬元以支付因上述問題而導致的預算赤字。該基金對本項目的總資助額提升至一億九百二十三萬元。

Members of the Project Management Committee 項目管理委員會委員名單

Chairman 主席:	Dr. Ko Wing-man	高永文醫生
Members 委員:	Mr. William Yiu Dr. Poon Yeuk-foo Mr. Davie Au-yeung Mr. Edwin Chiu Ngar-wing Dr. Pamela Leung	饒恩培先生 潘若芙醫生 歐陽贊邦先生 趙雅穎先生 梁明娟醫生
Project Manager 項目經理:	Ove Arup & Partners Hong Kong Ltd.	奧雅納工程顧問
Secretary 秘書:	Miss Iris Leung	梁小雲小姐

B) Hospital Commissioning 醫院籌備

Services Planning Committee 服務籌劃委員會

Membership of the Services Planning Committee 2007/08 2007/08年度服務籌劃委員會委員名單

Chairperson 主席:	Dr. Pamela Leung	梁明娟醫生
Ex-officio Members 執行委員會代表:	Dr. Ko Wing-man Dr. Poon Yeuk-foo Mr. Edwin Chiu Ngar-wing Mr. Davie Au-yeung	高永文醫生 潘若芙醫生 趙雅穎先生 歐陽贊邦先生
Members 委員:	Miss Betty M.Y. Au Ms. Christina Cheng Mr. Cheng Chung-hing Ms. Phoebe Fan Ms. Kedo Kwan Ms. Connie Lam Mr. Law Chi-keung Ms. Joyce Leung Kam-ling Miss Camila Li Mr. Hans Li Ms. Alisha Ma Hsiao-hung Ms. Angela Ng Dr. Sze Wai-man Dr. Tse Chun-yan Mrs. Pamela Tung Mrs. Agnes Wong Dr. Yau Chun-chung Ms. Wendy Yu Ms. Bonnie Wu	區美如小姐 鄭秀如女士 鄭重慶先生 范思樂女士 關婉薇女士 林婉雯女士 羅志強先生 梁錦玲女士 李淑儀小姐 李行思先生 馬奕彤女士 吳潤娥女士 施惠民醫生 謝俊仁醫生 董梁麗華女士 黃馮玉棠女士 邱振中醫生 余文詩女士 胡敏慧女士
Secretary 秘書:	Miss Iris Leung	梁小雲小姐

The 5 Task Groups under the Services Planning Committee continued their respective activities even more diligently to prepare for the commissioning of the Jockey Club Cancer Rehabilitation Centre's. In May 2008, works of the Services and Charges Task Group, the Inventory Task Group and the Facility Management Task Group were continued by the Commissioning team. The Commissioning team members were all full time staff of The Hong Kong Anti-Cancer Society under the superior leadership of our Honorary Hospital Superintendent Dr. Pamela Leung. This was so that the hospital commissioning works could be proceeded in full speed; in preparation for hospital registration and service commencement. We were most grateful to voluntary members of the Services Planning Committee, who continued to give invaluable advice to the commissioning team whenever they were being consulted.

服務籌劃委員會屬下的5個工作小組繼續努力地執行其工作範疇，以籌備賽馬會癌症康復中心開啟工作。2008年5月服務及收費工作小組、物資工作小組及設施管理小組繼續效力醫院籌備工作小組。醫院籌備工作小組的全體成員均為香港防癌會的全職人員，在義務醫務總監梁明娟醫生領導下執行工作。亦因此使醫院註冊籌備及開啟預備工作上能得以全力進行。我們非常感謝服務籌劃委員會所有義務委員繼續為醫院籌備工作小組提供他們寶貴的意見。

The IT Task Group continued to oversee the development of the IT system, with special emphasis on the development of the Clinical Information System for the JCCRC.

資訊科技工作小組繼續監測本會資訊科技系統，特別重點發展賽馬會癌症康復中心的臨床資訊系統。

Members 成員:

Dr. Yau Chun-chung (Convenor)
Dr. Pamela Leung
Dr. Sze Wai-man
Ms. Phoebe Fan
Miss Camila Li

邱振中醫生(會議召集人)
梁明娟醫生
施惠民醫生
范思樂女士
李淑儀小姐

The TCM Task Group continued its work to pave ways for the proposed opening of The Hong Kong Anti-Cancer Society Hong Kong Baptist University Chinese Medicine Centre in mid-January 2009, following the signing of a Memorandum of Understanding in January 2008 between the Society and the University.

中醫藥中心工作小組繼續其工作，為於2008年1月本會與浸會大學簽署合作協議備忘錄後，預計2009年1月中旬啟用的香港防癌會-浸會大學中醫藥中心作出準備。

Members 成員:

Dr. Pamela Leung (Convenor)
Dr. Poon Yeuk-foo
Mr. Law Chi-keung
Ms. Alexandra Lo
Dr. Sze Wai-man
Dr. Tse Chun-yan

梁明娟醫生(會議召集人)
潘若芙醫生
羅志強先生
羅德慧女士
施惠民醫生
謝俊仁醫生

Besides the Commissioning team, a **Quality & Risk Management Committee** and an **Infection Control Committee** were also formed to assist with the hospital commissioning work.

除醫院籌備工作小組外，我們亦成立了兩個委員會－**質量及風險管理委員會**和**傳染病監控委員會**以協助推行醫院的籌備工作。

Members of the Quality and Risk Management Committee
質量及風險管理委員會委員名單

Chairperson 主席:

Dr. Lillian Lau

劉麗蓮醫生

Members 委員:

Dr. Poon Yeuk-foo
Dr. Pamela Leung
Dr. Aye Kyu
Ms. Betty Au
Miss Iris Leung
Mr. Simon Lam
Ms. Betty Chang
Ms. Eunice Chan
Miss Katty Leung
Mr. Kevin Chung
Mr. William Kwong
Miss Ritty Mak
Mr. Lau Wai Kit
Mr. Stephen Cheung

潘若芙醫生
梁明娟醫生
蘇怡燒醫生
區美如女士
梁小雲小姐
林勝先生
張人瑛女士
陳淑貞女士
梁佩賢小姐
鍾啟生先生
鄺力沛先生
麥惠玲小姐
劉偉傑先生
張鴻德先生

Secretary 秘書:

Mr. Andy Leung

劉文偉先生

Members of the Infection Control Committee 傳染病監控委員會委員名單

Chairperson 主席:	Dr. Pamela Leung	梁明娟醫生
Members 委員:	Dr. Poon Yeuk-foo Dr. Vincent Cheng Dr. T.K. Que Dr. Aye Kyu Ms. Betty Au Miss Iris Leung Mr. Simon Lam Ms. Betty Chang Ms. Eunice Chan Miss Katty Leung Mr. Kevin Chung Mr. William Kwong Miss Ritty Mak Mr. Lau Wai Kit Mr. Stephen Cheung	潘若芙醫生 鄭智聰醫生 郭德麟醫生 蘇怡燒醫生 區美如女士 梁小雲小姐 林勝先生 張人瑛女士 陳淑貞女士 梁佩賢小姐 鍾啟生先生 鄺力沛先生 麥惠玲小姐 劉偉傑先生 張鴻德先生
Secretary 秘書:	Mr. Andy Leung	劉文偉先生

By early September 2008, Stage I of the hospital commissioning works were completed and we applied for hospital registration with the Department of Health, the Government of HKSAR. An inspection by the Department took place on 30 September 2008.

2008年9月上旬，第一期的醫院籌備工作已完成，因此我們向香港特別行政區政府的衛生署遞交有關註冊的申請。2008年9月30日該部門派員親臨巡察本院。

The Hong Kong Anti-Cancer Society Jockey Club Cancer Rehabilitation Centre was successfully registered as a hospital on 10 October 2008 with a Stage I opening of 28 beds for inpatients and various hospital services areas.

2008年10月10日香港防癌會賽馬會癌症康復中心成功註冊為一所醫院，並開啟第一期共28張病床病房，接受病人入住及提供一系列不同的醫院服務予病人。

C) The Hong Kong Anti-Cancer Society Jockey Club Cancer Rehabilitation Centre 香港防癌會賽馬會癌症康復中心

The Mission 宗旨

A caring “Home Away From Home” providing a wide range of services required by cancer patients at different phases of their illness and recovery; with special emphasis on integrated Western & Chinese medicine, quality nursing care, psychosocial and family support and rehabilitation.

我們致力提供一所服務範疇廣泛的「家以外之家」予癌病患者以照顧他們在患病期間不同階段的需要及復康護理；並特別着重中、西醫療的結合、優質的護理照顧、病者家庭的支援與康復活動。

Members of the Hospital Governing Committee 醫院管治委員會

Chairman 主席:	Dr. Ko Wing-man	高永文醫生
Ex-Officio Member 執行委員會代表:	Dr. Poon Yeuk-foo Dr. Pamela Leung	潘若芙醫生 梁明娟醫生
Members 委員:	Dr. Gordon Au Mr. Eric T.M. Cheung Mr. Peter Ko Ms. Alexandra Lo Ms. Ma Yuet Har Mr. William Po	歐國雄醫生 張達明律師 高德耀先生 羅德慧女士 馬月霞女士 蒲錦文先生
Secretary 秘書:	Miss Iris Leung	梁小雲小姐

Service to be delivered at the JCCRC 賽馬會癌症康復中心提供的服務

Services to be delivered at the JCCRC are best summarized by its Holistic Rehabilitation Program approach, taking care of all 4 aspects of cancer patients: (1) Physical; (2) Psychological; (3) Social; (4) Spiritual.

賽馬會癌症康復中心所提供的服務已概括在其全方位康復計劃中，為癌症病人提供(1)身、(2)心、(3)社、(4)靈四個範疇的服務。



Floor Plan of the Hong Kong Anti-Cancer Society Jockey Club Cancer Rehabilitation Centre 香港防癌會賽馬會癌症康復中心平面圖



- 3/F } 癌症康復病房
2/F } Cancer Rehabilitation Wards
1/F }


G/F 職員餐廳及靈修室
Staff Canteen & Spiritual Centre

- | | |
|-----|---|
| 9/F | 中醫藥中心 Chinese Medicine Centre |
| 8/F | 演講廳 Lecture Hall |
| 7/F | 香港防癌會行政部 HKACS Administration Office |
| 6/F | 義工活動及服務中心 Volunteers' Centre |
| 5/F | 日間暫托服務 / 留宿服務 Day Care / Overnight Rooms |
| 4/F | 紓緩護理中心 Palliative Care Centre |
| 3/F | 健體及物理治療中心 Wellness & Physiotherapy Centre |
| 2/F | 西醫門診 / 藥房 Out-Patient Centre / Pharmacy |
| G/F | 病人活動中心 Patient Activity Centre |

Organisation Structure of The Hong Kong Anti-Cancer Society 香港防癌會組織架構圖



Organisation Structure * of The Hong Kong Anti-Cancer Society Jockey Club Cancer Rehabilitation Centre 香港防癌會賽馬會癌症康復中心組織架構圖



* Brief Version
簡本

(Special Post-period Report 彙報期後的特別報告)

Soft Opening of the JCCRC 18 October 2008 賽馬會癌症康復中心試業啟用禮 2008年10月18日

A simple but meaningful soft-opening ceremony of the Centre took place on 18 October 2008 to mark a new milestone era of The Hong Kong Anti-Cancer Society.

一個簡單而隆重的賽馬會癌症康復中心試業啟用禮於2008年10月18日舉行，這標誌著香港防癌會步入新里程。



Administration & Finance 行政及財務

Membership of the Administration & Finance Subcommittee 2007/08 2007/08 年度行政及財務委員會委員名單

Chairman 主席:	Mr. Edwin Chiu Ngar-wing	趙雅穎先生
Members 委員:	Mr. Davie Au-yeung Dr. Hubert Chan Mr. Frank Jin Shui-seng Dr. Pamela Leung Mr. Hans Li Dr. Poon Yeuk-foo	歐陽贊邦先生 陳重義博士 金瑞生先生 梁明娟醫生 李行思先生 潘若芙醫生
Secretary 秘書:	Miss Iris Leung	梁小雲小姐

During the year, the Administration & Finance Subcommittee has created and employed the crucial posts for the commissioning of the Jockey Club Cancer Rehabilitation Centre, including the Medical Officer, Nursing Manager & Nursing Officer.

The Subcommittee has also formulated the investment policy for the Society and in view of the financial need of the Society during the initial stage of the JCCRC, it has recommended the Society to adopt the cash model of investment under which all cash in hand are kept in deposits with different maturities within 1 year.

匯報期間，行政及財務委員會為賽馬會癌症康復中心創設並委任關鍵崗位員工，以便推行開院前、後期的籌備工作，當中包括駐院醫生、護理總經理及護理主任等。

委員會亦為香港防癌會擬定投資策略，有鑑於賽馬會癌症康復中心仍在發展初階，因此建議本會採納靈活的現金投資模式——將庫存現金分配到不同存款期，以一年為限的定期存款，以配合本會的財務需要。

Recreational and Diversional Therapy Service 康樂治療小組服務

A new out-reaching recreational program, subvented by the Community Chest of Hong Kong, has started for home bound cancer patients on Hong Kong Island since in April 2004.

A variety of recreational activities were organized for home bound cancer patients in collaboration with other Hospital Authority hospitals. Festive celebrations and indoor activities were also organized for the in-patients at the hospitals in the region to alleviate their stress and tension due to illness; and to enable them to enjoy the festive mood. In addition, the provision of the volunteer service including hair cutting for cancer patients were invited by Grantham Hospital. Regular home visits to cancer patients under home palliative care, who lacked social support were continued.

“Make a Wish” program was an unique feature of the out-reaching program to allow terminally ill patients to express their wishes freely with positive support.

自2004年4月開始，一個全新的由香港公益金資助的外展康樂服務，為港島區的居家癌症病人提供服務。

小組亦與醫院管理局的醫院合作舉辦多元化康樂活動予居家的癌症病人。為屬區醫院的住院病人籌辦戶外活動及在節慶日子舉行慶祝活動，以紓緩他們因疾病導致的壓力和不安情緒，同時讓他們同享節日的歡樂氣氛。此外，小組獲葛量洪醫院的邀請為該院的癌症病人提供義工服務包括理髮等；小組亦為缺乏社交支援的居家休養癌症病人提供定期的家訪。

「願望成真」計劃是外展康樂服務的獨特節目，目的是讓晚期病人隨心所欲表達他們的願望，盡可能在本會的協助下得償所願。

Summer training courses for secondary school students were organized to arouse public concern for the well-being and needs of cancer sufferers. Visitation to cancer patients has also been arranged to enrich the students' life experience in showing their concern for the ill and unfortunate fellow citizens.

小組亦為中學生舉辦暑期訓練課程，以喚起大眾關注癌症病人的福祉和需要。此外，小組亦會安排學生探訪癌症病人，藉以豐富他們的人生經驗，對病患及不幸者加以關懷。

Statistics for Recreational & Diversional Therapy Service

康樂治療服務統計表

01/10/2007 – 30/09/2008

Service area 服務範圍	No. of activities held / event completed 舉行活動次數 / 已完成的活動	Total no. of participants 總參與人數	Duration per activity 每個活動 的時間
1 Festival Function for home care cancer patients 為居家癌症病人提供的節慶活動	4	233	2 hours 小時
2 Indoor activities for 提供室內活動予： Home care cancer patients of Ruttonjee Hospital 律敦治醫院的家居癌症病人 Home care cancer patients of Grantham Hospital 葛量洪醫院的家居癌症病人 Cancer ward patients of Grantham Hospital 葛量洪醫院癌症病房的院友	4 2 39	50 21 124	2 hours 小時
3 Outdoor activities for home care cancer patients in Hong Kong Island 為港島區的家居癌症病人提供的戶外活動	8	183	4½ hours 小時
4 A short term volunteer training course for secondary students 為中學生提供的短期義工訓練課程	3	80	3½ hours 小時
5 Providing free hair cutting for cancer patients at Grantham Hospital 為葛量洪醫院癌症病人提供免費理髮服務	11	219	2 hours 小時
6 Initiate “Make a wish” program to terminally ill cancer patients 實施晚期病人「願望成真」計劃	30	30	7 hours 小時
7 Home visit for home-stay cancer patients under palliative care 為居家休養的癌症病人提供家訪	200	50	2 hours 小時
8 Relatives Support Group and Peer Support Group 舉辦家屬支援小組及同儕支援小組	8	60	2½ hours 小時



Volunteers organized a recreation program for cancer patients during summer time
暑假期間本會義工籌辦康樂活動予癌症病人



Joint function with Palliative Care Unit of Ruttonjee Hospital
與律敦治醫院的舒緩護理小組一起合辦康樂活動



A well-known artist was invited to perform at Christmas Party
著名藝人獲邀在聖誕聚會中為出席者高歌一曲



Santa Clause gave Christmas presents to discharged cancer patients
聖誕老人派禮物給已出院的家居癌症病人



Carol singing to participants at Sai Yin Pun Western Community Center
聖詩班在位於西營盤的西區社區中心為參與者高唱聖歌



Participants enjoyed lunch buffet at Tsim Sha Tsui's restaurant
參與者在尖沙咀一間食肆享受豐富的自助午餐



Discharged patients and their family members were picked up to Tsim Sha Tsui East for sight seeing
已康復出院的癌症病人與家人一起前往尖沙咀東部觀光



Visited Hong Kong Museum of Art
參觀香港藝術館



Visited Pre-Chinese New Year Flower Market at Victoria Park
日間出席參觀維多利亞公園年宵市場的花市



Visited Nan Lian Garden at Diamond Hill
參觀位於鑽石山的南蓮園池



Lunar new year function held on 6th floor Volunteers' Centre, Jockey Club Cancer Rehabilitation Centre
在位於香港防癌會賽馬會癌症康復中心六樓的義工中心舉行農曆新年活動



Joint program with Palliative Care Unit of Grantham Hospital
與葛量洪醫院的紓緩護理小組一起合辦康樂活動



Summer training course for Secondary Students to become volunteers
為中學生舉辦暑期義工訓練課程



Tutor taught students how to twist balloons
導師向學員教導示範扭汽球



Tutor demonstrated magic tricks to students
導師為學員示範魔術竅門



Trained volunteers launched a recreation program to day care patients
訓練有素的義工為日間護理病人展開康樂活動計劃



Home-stay cancer patients were brought to Stanley for sight seeing
家居癌症病人一起前往赤柱觀光



Home-stay cancer patients enjoyed afternoon tea at Repulse Bay
家居癌症病人悠閒地在淺水灣享受下午茶

BETTERMENT FOR CANCER PATIENTS 改善癌病人生活

Membership of the Betterment Fund Subcommittee 2007/08 2007/08 年度【改善癌病人生活基金委員會】委員名單

Chairperson 主席:	Mrs. Agnes Wong	黃馮玉棠女士
Secretary 秘書:	Miss Wennie Wong	黃小玲小姐
Members 委員:	Mrs. Chu Lo Shin-yee Mrs. Prudence Lau Wing-may Mrs. Esther Mak Mrs. Judy Mauldon Ms. Gloria Ng Yin Ping Mrs. Laura Sin Mrs. Helen Sinn Miss Tan Lian-hong Mrs. Carmen Yam	朱盧倩儀女士 劉葉詠媚女士 麥楊秀蘭女士 毛陳超華女士 吳燕萍女士 冼李燕萍女士 冼陳淑霞女士 陳蓮舫女士 任梁嘉曼女士

The Betterment Fund Subcommittee was originally formed to administer “Betterment Fund for Cancer Patients” to provide direct financial assistance to cancer patients for meeting their non basic needs and to support group activities organised for them. Later on, it also administers (i) the Prof. H.C. Ho Memorial Assistance Program; (ii) the Supportive Medical Assistance Program; (iii) the Portia Cheung Breast Cancer Support Program and (iv) the Late Madam Tsui Sang Fund. Applications submitted by medical social workers on patients’ behalf, were vetted and approved by the Subcommittee on individual merit.

The Fund has been supported by the Hong Kong Jockey Club Charities Trust and public donations. The “Jockey Club Cares for Cancer Patients” program under the 3-year Community Project Grant (CPG) was designated to provide direct financial assistance to individual cancer patients. The annual grant was \$440,000.

【改善癌病人生活基金委員會】起初被成立以管理為癌症病人而設的『改善癌病人生活』基金，基金提供直接資助予癌症病人以應付其額外需要，同時亦支援各項為癌病患者籌劃的團體活動。委員會其後更兼管：(i)「何鴻超教授紀念助醫計劃」；(ii)「癌症病人慈惠助醫計劃」；(iii)「張謝寶英乳癌康復資助計劃」及 (iv)「已故崔生女士基金」。各項申請需由醫務社工代為申辦，委員會則按個別病人的情況加以審批。

『改善癌病人生活』基金主要有賴香港賽馬會慈善信託基金支持及廣大市民的捐助。由香港賽馬會慈善信託基金資助，為期三年的香港賽馬會社區資助計劃－「關懷癌症病人計劃」本年度撥款共港幣440,000元，用以提供直接資助予個別癌症病人。

During the year under review, a total of 172 applications were received for the Betterment Fund of which 156 were approved. Total disbursements amounted to \$661,231:

在匯報年度內，『改善癌病人生活』基金共接獲172宗資助申請，156宗獲審批。合共支出港幣661,231元，其中


- 58% (\$382,870.25) was drawn from the fund provided by the Hong Kong Jockey Club Charities Trust - Community Project Grant.
58% (382,870.25元) 由香港賽馬會慈善信託基金 — 社區資助計劃撥付。
- 27% (\$178,731) from public donations.
27% (178,731元) 由公眾捐款中撥付。
- 7.8% (\$52,000) from Portia Cheung Breast Cancer Support Program.
7.8% (52,000元) 由「張謝寶英乳癌康復資助計劃」中撥付。
- 6.4% (\$42,000) from the late Madam Tsui Sang Fund.
6.4% (42,000元) 由「已故崔生女士基金」中撥付。
- 0.8% (\$5,629.75) from the outstanding balance of Brewin Trust Fund.
0.8% (5,629.75元) 由蒲魯賢慈善信託基金的餘額中撥付。

Requests from individual cancer patients for financial assistance for obtaining extra nourishment represented 71.2% of the total disbursement.

個別癌症病人要求資助額外營養品的申請佔總支出的71.2%。

- applications to support various indoor and outdoor activities for cancer patients and their families amounted to 12.2%. A total of 3,013 patients had participated in these functions.
資助為癌症病人及其家人安排的戶內和戶外活動的申請佔12.2%，共有3,013名病患者參與活動。
- the remaining 16.6% were disbursed for granting requests for medical and rehabilitation appliances and travelling expenses.
資助醫療及復康用品和交通費的申請佔餘下的16.6%。

Total disbursement
支付項目



Other Special Programs 其他兼管項目

I. Prof. H.C. Ho Memorial Assistance Program 「何鴻超教授紀念助醫計劃」

Since the program was implemented in February 2006, 1,316 applications for assistance were received from the six hospitals of which 1,095 were approved:

自計劃於2006年2月推出後，共接獲來自六間醫院的1,316宗資助申請，其中1,095宗獲批准：


Hospital 醫院	Approved Cases for the period 1 October 2007 to 30 September 2008 2007年10月1日至2008年 9月30日期間獲審批個案	Approved Cases accumulated since February 2006 自2006年2月始 累積審批個案
Pamela Youde Nethersole Eastern Hospital 東區尤德夫人那打素醫院	27 cases 宗	110 cases 宗
Prince of Wales Hospital 威爾斯親王醫院	80 cases 宗	248 cases 宗
Princess Margaret Hospital 瑪嘉烈醫院	66 cases 宗	150 cases 宗
Queen Elizabeth Hospital 伊利沙伯醫院	197 cases 宗	525 cases 宗
Queen Mary Hospital 瑪麗醫院	21 cases 宗	71 cases 宗
Tuen Mun Hospital 屯門醫院	97 cases 宗	212 cases 宗
總數	488 cases 宗	1,316 cases 宗
Applications approved for full drug sponsorship 獲批准全數藥物贊助的申請	170 cases 宗 (40.58%)	330 cases 宗 (30.14%)
Applications approved for partial sponsorship 獲批准部份現金資助及部份藥物贊助的申請	79 cases 宗 (18.85%)	216 cases 宗 (19.72%)
Applications approved for financial assistance 獲批准全數現金資助的申請	170 cases 宗 (40.57%)	549 cases 宗 (50.14%)
No. of applications not recommended by medical social workers 不獲醫務社工推薦的申請	31 cases 宗	42 cases 宗
Allocation for partial sponsorship 部份資助的分配額	\$423,864	\$1,298,226
Allocation for financial assistance 全數資助的分配額	\$1,728,485	\$6,902,631
Total allocation 總分配額	\$2,152,349	\$8,200,857

Our heartfelt thanks went to the following four pharmaceutical companies for their generous donations in-kind added up to around \$24,537,990.50 for 7 types of cancer drugs:

本會非常感謝下列四間製藥公司的鼎力支持，共贊助七種癌症治療藥物，總值約港幣24,537,990.50元:

1	Eli Lilly Asia, Inc. 美國禮來公司	\$15,609,000.00
2	Roche Hong Kong Limited 羅氏大藥廠香港有限公司	\$4,889,030.50
3	sanofi-aventis Group 賽諾菲安萬特製藥集團	\$2,919,960.00
4	GlaxoSmithKline Hong Kong 香港葛蘭素史克	\$1,120,000.00
		<u>\$24,537,990.50</u>

Approved applicants of Prof. H.C. Ho Memorial Assistance Program 「何鴻超教授紀念助醫計劃」獲批的申請



A specially organised fund raising event: a walkathon on 30 March 2008 was dedicated to raising fund to sustain the Program. (Please see Fundraising & Publicity Subcommittee Report section for event details).

匯報期間內舉辦了一個特別的籌款活動，於2008年3月30日舉行了慈善步行籌款（活動詳情刊於籌募及推廣委員會報告欄）。

II. The Supportive Medical Assistance Program 「癌症病人慈惠助醫計劃」

This program was commenced in July 2006. It adopts the assessment criteria and application procedures which are basically the same as those of the Prof. H.C. Ho Memorial Assistance Program except that the maximum amount of sponsorship that can be granted to a successful application is HK\$200,000 (subject to extension at the discretion of the Society in exceptional circumstances) and that applicant would need to fulfill certain additional hardship criteria laid down for this program.

Between the period of October 2006 and September 2008, there were ten successful applications and the Society has undertaken to sponsor all or most of the estimated costs of the self-financed cancer drugs of the successful applicants in question.

本計劃於2006年7月開始，計劃採用的評審準則及申請程序基本上與「何鴻超教授紀念助醫計劃」大致相同，所不同的是成功申請者的資助金額最高可獲港幣200,000元（在特殊情況下本會可再考慮提高資助額），及申請人需符合本計劃額外訂定的一些家境困難準則。

在2006年10月至2008年9月期間，共有十名申請者成功獲得批准資助。本會將資助該五名成功申請者需自費購買癌症治療藥物整個療程的全部或大部份的藥物開支。

III. Portia Cheung Breast Cancer Support Programme 「張謝寶英乳癌康復資助計劃」

This program, Portia Cheung Breast Cancer Support Programme under the Betterment Fund for Cancer Patients, was established in March 2007 in memory of Mrs. Portia Cheung Tse Po Ying who died of breast cancer in February 2007.

The main objective of the Programme is to help and support needy individual breast cancer patients and their families in areas not currently funded by the Government or other sources.

As at 30 September 2008, donations in a total sum of \$1,017,721 were received from the family and friends of the late Portia Cheung. Up to date 24 Breast cancer patients have been benefited from this program with total disbursements amounted to \$84,000.

由『改善癌病人生活』基金管理的「張謝寶英乳癌康復資助計劃」於2007年3月成立，以紀念於2007年2月因乳癌病逝的張謝寶英女士。

該計劃的主要目的是幫助及照顧個別乳癌患者及其家人的一些需要，而該些需要是目前不獲政府或其他資源資助的。

截至2008年9月30日止該計劃共接獲來自張謝寶英女士的親屬和朋友的慷慨捐款共港幣1,017,721元。至今共有24名乳癌患者受惠於這計劃，而資助總額為港幣84,000元。

IV. Gift from the late Madam Tsui Sang 「已故崔生女士基金」

In February 2007, the late Madam Tsui Sang had generous willed \$1M. of her estate as donation to our Society, of which \$600,000 was allocated to usage for drug assistance to any cancer sufferers over age 65 via our Society's Prof. H.C. Ho Memorial Assistance Program (HCHMAP); and the remaining \$400,000 was designated for the Betterment Fund for Cancer Patients.

As at 30 September 2008, there were 53 eligible cancer patients of HCHMAP successfully received the financial assistance sum up to \$339,323, meanwhile, a total sum of \$42,000 were granted to 12 cancer patients from H.A. hospitals through the Betterment Fund for Cancer patients for obtaining extra nourishment.

2007年2月，已故崔生女士於其遺囑上慷慨饋贈港幣壹百萬元予香港防癌會，其中600,000元分配至本會「何鴻超教授紀念助醫計劃」，用於藥物資助65歲以上之癌症病人；而餘下之400,000元撥歸『改善癌病人生活』基金之用。

截至2008年9月30日，共有53名合資格的「何鴻超教授紀念助醫計劃」申請人獲得資助，總數共339,323元，同時，來自醫院管理局醫院的12名癌症病人透過『改善癌病人生活』基金獲得共42,000元資助以購買額外營養品。

CANCER EDUCATION 癌症教育

CANCER DETECTION AND PREVENTION 癌症探測及預防

Both Subcommittees work pro-actively to keep the public & health professionals informed of the latest cancer-related knowledge and the evidence-based means of early detection, aiming at empowering people to take a sensible step towards the direction of cancer prevention.

With invaluable support from experts & volunteers of all fields, educational programs were able to reach the most needy public, patients and health professionals in a most cost-effective manner. Major events are listed below chronologically for your perusal.

癌症教育與癌症探測及預防兩個委員會繼續積極地從事癌症教育工作，為普羅大眾及專業醫護人員提供最新的癌症資訊及經研究證實有效的探測方法，目的是加強市民自發性預防癌症。

本會在各方的專業人士及義工寶貴的協助下，癌症教育才得以有效地伸延至有需要的市民、病人及專業醫護人員。以下是本會按時序先後列出主要項目以供參閱。

Membership of the Cancer Education Subcommittee 2007/08 2007/08年度癌症教育委員會委員名單

Chairman 主席:	Dr. Daniel Chua	蔡清澳醫生
Members 委員:	Dr. Ashley C.K. Cheng	鄭志堅醫生
	Ms. Cheung Pui Lan	張佩蘭女士
	Dr. William Foo	傅惠霖醫生
	Dr. Fu Yiu Tung	傅耀彤醫生
	Dr. Carol Kwok Chi Hei	郭子熹醫生
	Dr. Anne Lee Wing Mui	李詠梅醫生
	Mrs. Tammy Lee	李周翠娥女士
	Dr. Leung Sing Fai	梁承暉醫生
	Mrs. Gloria Li	李劉佩驊女士
	Dr. Liu Chi Leung	廖子良醫生
	Ms. Faith Liu Chun Fong	廖進芳女士
	Dr. Liu King Yin, Rico	廖敬賢醫生
	Dr. Luk Mai Yee	陸美儀醫生
	Dr. Ng Wai Tong	吳偉棠醫生
	Prof. Frances Wong	黃金月教授
	Dr. Yau Chun Chung	邱振中醫生
	Dr. Yau Tze Kok	游子覺醫生
	Dr. Anthony Ying	應志浩醫生
	Ms. Jacqueline Yuen	原家翠女士
Secretary 秘書:	Miss Iris Leung	梁小雲小姐

Membership of the Cancer Detection and Prevention Subcommittee 2007/08 2007/08年度癌症探測及預防委員會委員名單

Chairman 主席:	Dr. Anthony C.H. Ying	應志浩醫生
Members 委員:	Dr. Daniel Chua Tsin Tien Prof. Albert Lee Dr. Francis Mok Dr. Rebecca Yeung Mei Wan	蔡清洵醫生 李大拔教授 莫俊強醫生 楊美雲醫生
Advisor 顧問:	Dr. Caroline S.H. Tsang	曾守衡醫生
Secretary 秘書:	Miss Iris Leung	梁小雲小姐
Senior Education officer 高級教育主任:	Mrs. Tammy Lee	李周翠娥女士

Report for the period 1 October 2007 – 30 September 2008 2007年10月1日至2008年9月30日期間的報告



October 2007 – Cervical Cancer Program: Seminar delivered by Prof. Annie Cheung & Dr. Keith Lo. 260 people attended. The talk was later made into educational VCD and distributed to public and patients.

2007年10月—「子宮頸癌：預防與治療突破性進展」項目：專題講座由張雅賢教授及盧永傑醫生主講，共有260名市民出席。而有關講座已製錄成教育光碟派贈與市民及病患者。

October-November 2007 – A 8-week Cancer Nursing Course was organized jointly with HKU-PMH Cancer Education & Research Centre and PMH. 203 nurses attended and 98% of them attained 85% attendance. 94.7% commented the course as satisfactory to very satisfactory.

2007年10至11月—香港大學及瑪嘉烈醫院癌症教研中心、瑪嘉烈醫院及本會合辦為期八星期的癌症護理課程，共有230名護士參與，其中百份之九十八學員出席率達百份之八十五，百份之九十四點七學員對課程給予滿意至非常滿意的評價。

October 2007 – Press conference on Brain Tumour: Survey on “Public Perception on Brain Tumour” was conducted by HKUPOP and results were presented by Dr. Daniel Chua. Sharing from ex-patient, Miss Hui and her mother was most touching. It was reported by several major newspapers.

2007年10月—「腦癌知多少」問卷調查發布會：蔡清洵醫生公布由本會委託香港大學民意研究中心進行有關「市民對腦癌的認知」問卷調查結果。會上腦癌康復者許小姐和她的母親與出席者分享她的患病經歷，感人肺腑。而本港主要報章均有報導。



November 2007 – Thyroid Cancer Program: Dr. Chow Sin Ming and Dr. Ho Chiu Ming spoke live on Radio program 精靈一點. Seminar was delivered by Dr. Chow Sin Ming and Dr. Lo Chung Yau and attended by 340 people. The booklet was written by Dr. Chow Sin Ming and Dr. Ho Chiu Ming.

2007年11月—「全方位認識甲狀腺癌」項目：周倩明醫生與何昭明醫生出席電台直播節目「精靈一點」講解甲狀腺癌。周倩明醫生與盧寵猷醫生主講有關講座，共有340名市民出席。「認識甲狀腺癌」小冊子則由周倩明醫生及何昭明醫生共同撰寫。



January-April 2008 – CADENZA Professional Integrated Oncology, Palliative & Elderly Course: The HK Jockey Club Charity Trust approved 3 years funding to the Society to organize courses biannually for nurses. The course comprises 48-hour lectures and field visits. 330 applications received and 83 were registered. Post-course evaluation revealed 100% satisfactory rate. The July-Oct course admits 62 nurses and is still in process.

2008年1月至4月—「流金頌—癌症、紓緩及老人專業護理課程」：此由香港賽馬會慈善信託基金資助。課程包括含48小時講課及實地參觀。首課程共接獲330個申請，惟名額有限只有83名申請者獲接納參與。課後進行的評估顯示學員對課程滿意程度達百份之百。7月至10月的課程現正本會址進行，共有62名護理人員登記。



March-Aug 2008 – Cervical Cancer Prevention TV Info-Series: Eight 10-seconds episodes were produced in March and subsequently broadcast on TVB in May-Aug to raise public awareness on the subject. Prof. Hextan Ngan, Dr. Grace Wong, Dr. Cheung Tak Hong, Dr. Keith Lo, Dr. Ko Wing Man, Dr. Anthony Ying and Dr. Daniel Chua and Miss Charlene Choi kindly rendered their professional input to the series.

2008年3月至8月—預防子宮頸癌電視資訊系列：本年3月共製作了八集每集10秒的資訊系列並於5月至8月期間在無綫電視翡翠台播出，以喚起市民對該疾病的關注。非常感謝顏婉嫦教授、黃靜妍醫生、張德康醫生、盧永傑醫生、高永文醫生、應志浩醫生、蔡清洸醫生及蔡卓妍小姐為這資訊系列提供專業意見及戮力參與。



April 2008 – Cervical Vaccines Donation Scheme Seminar & Press Conference: Conducted by Dr. Ko Wing Man and Dr. Anthony Ying and attended by 195 people, including press, NGO representatives, social workers and health workers. It was duly reported by newspapers and electronic press.

2008年4月—子宮頸癌疫苗捐贈計劃、講座及新聞發布會：由高永文醫生及應志浩醫生主持的新聞發布會共有195名市民參與，當中包括傳媒、非牟利組織成員、社會工作者及醫護人員。會後均獲本地報章及電子傳媒廣泛報導。



April 2008 – Management of Treatment Side-Effects Program: Seminar was delivered by Dr. Donna Lee, Dr. James Ho and Ms Jacqueline Yuen. 280 people attended despite treacherous weather on the day. DVD was made out of the talk. A booklet was written by Dr. Carol Kwok.

2008年4月—「全高清認識癌症治療」項目：專業講座由李舒雅醫生、何重文醫生及原家翠女士主講，共有280名市民無懼當日惡劣的天氣熱忱參與。講座其後製錄成數碼影碟派贈市民。「全高清認識癌症治療」小冊子則由郭子熹醫生撰寫。



May 2008 – Skin Cancer Program: Dr. HO Chiu Ming & Dr. Anthony Ying delivered a talk to 120 public on 24 May. A DVD will be produced out of the talk

2008年5月—「皮膚癌的預防及治療」項目：專業講座何昭明醫生及應志浩醫生主講，共有120名市民參與。有關講座將製錄成數碼影碟派贈市民。

Press conference was held to further raise the importance of sun protection on 26 May. There were a total of 13 subsequent press coverage, including Apple Daily, Ming Pao Daily, South China Morning Post and Commercial Radio & RTHK.

5月26日舉行新聞發布會以進一步提醒市民在烈日下做足防預措施的重要性。其後共有13間傳媒機構發布該資訊，包括：蘋果日報、明報、南華早報、商業電台及香港電台。

After Dr. Anthony convened with the HK Observatory, a short advisory message is now installed in the hourly weather bulletin when UV index reaches 11 or above to remind the public to take precaution under the sun.

應醫生與香港天文台舉行會議達成共識，當紫外線指數強度達至11或以上時，天文台會在每小時的天氣報告中發出簡短忠告聲明以提醒市民在烈日下需採取適當的防曬措施。



The Education Bureau supports our mission on sun protection and has incorporated our guidelines in their “Outdoor Activities Guidelines” for Schools and Teachers’ observance.

教育局亦非常支持本會推行的「防曬行動」公眾教育，將有關指引納入其「活外活動指引」中讓學校及教師有所遵循。

Letters were sent to 2,100 primary & secondary schools, kindergartens, uniform groups, youth centres and hospitals. 96 of them responded requesting 37,000 copies of booklets and 2,300 posters. 11 schools requested talks and 6 of them already conducted to 2,500 students & parents.

暑假前，本會共致函2,100封至全港中、小學、幼稚園、制服團體、青少年中心及醫院。其中的96間機構回應索取共37,000本「預防皮膚癌」的小冊子及2,300張「預防皮膚癌」海報。共11所學校要求提供有關講座，彙報期間已為6間學校2,500名師生及家長舉行講座。



June 2008 – Liver Cancer Program: Seminar was delivered by Dr. Lui Chi Leung and Dr. Thomas Leung. 310 people attended. DVD was made out of the talk. A booklet was written by Prof. Fan Sheung Tat's team.

2008年6月—「全高清認識肝癌」項目：由廖子良醫生及梁惠棠醫生主講專業講座，共有310名市民參與。講座其後亦製錄成數碼影碟派贈市民。「肝癌淺釋」一書則由范上達教授等專科醫生撰寫。



July 2008 – Cancer Screening, Early Detection & Risk Factors Seminar was delivered by Dr. Law Chun Key and Dr. Anthony Ying. 325 people attended. The good attendance demonstrated that the public are keen to make good investment in their health for the future.

2008年7月—「癌症的高發因素、探測及預防」講座由羅振基醫生及應志浩醫生主講。共325名市民參與。市民的熱忱參與正好論證大眾對自身將來健康的重視及投入。



July 2008 – Health Expo organized by Eastern District Council and PYNEH: The Society was invited to organize a booth to education public about cancer prevention. The Wheel of Fat/Fibre was proved to be popular among receptive attendees.

2008年7月—本會護邀在由東區區議會及東區尤德夫人那打素醫院合辦的健康博覽會中設立攤位，為市民提供預防癌症的教育資訊。本會製作的『脂肪/纖維幸運輪』非常受市民的歡迎。



Sept 2008 – Gastric Cancer Program: Talk was delivered by Prof. Ng Kwok Wai and Dr. Raymond Chan. 290 people attended. Mr. Leung was confident to talk about his experience in the battle against gastric cancer. An educational DVD will be made out of the talk.

2008年9月—「全方位認識胃癌」項目：由吳國偉教授及陳子棠醫生主講的專題講座，共有290名市民出席。期間胃癌患者梁先生勇敢地道出他與胃癌搏鬥的經歷，發人深醒。講座亦會製錄成數碼影碟派贈市民。



Sept 2008 & onwards – Cervical Vaccines Donation Scheme: This is to offer the under-privileged young girls a chance to protect themselves against cervical cancer. Applications came from 17 NGOs, including Family Planning Association, Cancer Fund, Diabetic Association and ethnic minority group, requesting some 1,000 places. After discussion, MSD donated 150 places (2007-08) and 205 places (2008-09) to the Society. The first vaccination session was held in Tin Shui Wai & Yuen Long. All recipients were well-informed and consents were obtained. Pilot scheme was carried out in Po Leung Kuk and is progressing well. Our thanks go to Dr. Chu Chop Lup and Ms Chan Lai Ling for their support in the vaccination.

2008年9月至期後 — 子宮頸癌疫苗捐贈計劃：此計劃為弱勢社群的年青婦女提供一個預防子宮頸癌的機會。共接獲17間非牟利機構，包括香港家庭計劃指導會、癌症基金會、糖尿病協會及少數種族組織等超過1,000個的申請。經與贊助機構—香港默沙東協商後，該公司捐助分別150個名額(2007/08)及205個名額(2008/09)予本會。首疫苗接種環節於天水圍及元朗舉行。這創新計劃已於6月份在保良局推行，進展順利。所有受惠者均接受仔細輔導後簽署同意書。本會感謝朱初立醫生及陳麗玲姑娘義務協助注射的工作。



Cancer Screening & Health Counseling Project: It is funded by the Community Chest and targeted to launch in August. An experienced nurse takes on board the task of providing individualized counseling for those with family history of Nasopharyngeal, Colorectal, Breast and Liver cancers or Hepatitis B carrier. Our objective is to assist people to evaluate their own health status, assess cancer risk, empower them to materialize healthy living habits and implement regular early detection program. Advice & information given are evidence-based and in accordance with international standard. Sessions are running from HKACS office and HA Oncology Centres.

防癌輔導及諮詢服務：這服務由香港公益金資助，已於本年8月推行。一名資深護士負責有關的工作，為有鼻咽癌、大腸癌、乳癌及肝癌及乙型肝炎帶病毒病者，病者身親屬提供個別的輔導。目的是協助市民作出健康情況進行評價、癌病風險的評估、實踐健康生活模式和定期進行早期癌症計劃。所有提供的建議及資訊均建基於科學根據及符合國際標準。服務已在本會及醫院管理局屬下腫瘤部門中進行。

Press Exposures 傳媒專訪

Spokesperson & Topic 發言人及題目	Press 傳媒機構
Dr. Anthony Ying on Diet for Cancer patients 應志浩醫生－癌症病人的飲食	Apple Daily 蘋果日報
The Society's exiting material on General cancer 本會現存癌症資料	Ming Pao Online Education Web 明報育網站
Dr. William FOO on Bladder Cancer 傅惠霖醫生－膀胱癌	Associated Press News Agency 美國聯合通訊社
Dr. Anthony Ying on Cancer Risk & Night Shift 應志浩醫生－夜班工作與癌症的風險	Apple Daily 蘋果日報
Ms Faith LIU on Palliative care 廖進芳女士－舒緩護理	HK Economic Times 香港經濟日報
Dr. Anthony Ying on Mobile Phone and Oral Cancer 應志浩醫生－流動電話與口腔癌	Ming Pao 明報
Dr. Anthony Ying on Cancer Screening and Early Detection 應志浩醫生－癌症普查與早期探測	Ming Pao Weekly 明報周刊
Dr. Anthony Ying on Sun Protection & Skin Cancer 應志浩醫生－烈日防曬保護與皮膚癌	Sudden Weekly July issue 忽然一周7月刊
Dr. Anthony Ying on Skin Cancer 應志浩醫生－皮膚癌	生命力健康雜誌Aug issue 生命力健康雜誌8月刊
Dr. Anthony Ying on Thymus Gland tumour 應志浩醫生－胸腺腫瘤	HK Economic Times 香港經濟日報
Dr. Anthony Ying on Skin Cancer 應志浩醫生－皮膚癌	TVB Pearl Report 無綫電視「明珠檔案」
Dr. Anthony Ying on Benefits of Vitamin C to Cancer Patients 應志浩醫生－維生素c 與癌病人	HK Economic Times 香港經濟日報
Dr. Anthony Ying on Skin Cancer 應志浩醫生－皮膚癌	HK Economic Times 香港經濟日報
Dr. Anthony Ying on Paget's Disease of the Nipple and Breast 應志浩醫生－佩吉特氏病(乳頭和乳房膿腫)	HK Economic Times 香港經濟日報
Dr. Anthony Ying on Parotid gland Cancer & Use of Mobile Phone 應志浩醫生－腮腺癌與流動電話的使用	Oriental Daily 東方日報



Website: We endeavour to provide public a comprehensive pool of information on cancer aetiology, manifestation, diagnosis, treatment, nutrition, early detection and prevention. We also provide evidence-based advice on some hot issues concerning cancer to allay public anxiety.

本會網頁：我們竭誠提供一個綜合癌症成因、表現、診斷、治療、營養、早期探測及預防的資訊平台予市民瀏覽。同時亦為坊間極為關注有關癌症的熱門話題提供科學論證以緩和大眾的疑慮。



School & Community Education Program: 30 talks have been conducted at schools, community groups and workplaces to 6,000 students, parents, teachers and public. 548 telephone and 220 e-mail enquires have been handled.

學校及社區的癌症教育計劃：為學校、社區小組及工作場所共舉辦了30個講座，共6,000名師生、家長及公眾人士參與。本年度分別處理共548個來電及220個電郵就有關癌症的查詢作出回應。



Regular Health Columns: The Society maintains constant exposure in the weekly health column on "am730 Daily" and bi-monthly Rehab Express. Currently there are 25 different kinds of booklets/VCD/educational tools available and we distribute over 60,000 items to hospitals, clinics, patient groups and libraries upon their requests annually.

定期性健康專欄：本會仍維持在am730日報的每周專欄「醫理」及雙月刊「復康速遞」提供有關癌症資訊。目前本會共備有25款不同種類的小冊子/光碟/教育工具予市民取閱和使用。因應需求本年共分發了60,000 品目予醫院、診所、病人組織和圖書館。

Activities of Cancer Comrades 「同路人」的活動

The “Cancer Comrades” was formed in 1996 under the Cancer Education Subcommittee by a group of recovered cancer sufferers who volunteered to provide advice, support and care to cancer sufferers through experience sharing, hotline service and cancer education programs.

「同路人」成立於1996年，由一群癌病康復者組成，是本會癌症教育委員會轄下的義工。他們以癌病過來人的身份，透過經驗分享、熱線服務及參與癌症教育計劃等活動，義務為癌症病人提供康復心得、予以鼓勵關懷。

Membership of the Cancer Comrades 2007/08 2007/08年度「同路人」委員名單

Chairperson 主席:	Ms. Cheung Pui-lan	張佩蘭女士
Vice-Chairman 副主席:	Mr. Edward Tang Wah-kwai	鄧華桂先生
Members 委員:	Ms. Eva Chan Mr. Cheng Chung-hing Mr. Ho Kim-bor Ms. Rosanna Lau Ms. Windy Mak Ms. Tracy Wong Ms. Josephine Yuen Pui-jane Ms Patricia Leung Pik-kwan	陳玉梅女士 鄭重慶先生 何儉波先生 劉鳳卿女士 麥潔玲女士 黃翠珊女士 袁佩珍女士 梁碧君女士



(i) Telephone counseling 電話諮詢

The Cancer Hotline, manned by Ms. Cheung Pui-lan and Mr. Tang Wah-kwai had received about 100 calls. It took more than 15 minutes on average to answer each call.

In addition to answering public's enquiries, Ms. Cheung Pui Lan has also committed herself to visiting, meeting and giving support to cancer patients by emails on needed basis.

由「同路人」成員張佩蘭女士及鄧華桂先生一起主持及解答的「癌病熱線」，繼續為市民提供服務。在上述期間熱線共接獲約100多個電話查詢，處理每個諮詢電話需時平均超過15分鐘。


除回答公眾的電話諮詢外，張佩蘭女士在有需要時亦會探訪、會見及透過電郵提供支援予癌症病人。

(ii) Educational Book 癌症教育刊物

During the report period, Ms. Cheung Pui Lan has consolidated materials, maintained contacts with cancer patients, wrote cases of cancer patients for an educational book to be published by Cosmo Publisher.

在匯報期間，張佩蘭女士正密鑼緊鼓收集有關資料、與病人絡等工作，以便撰寫一本以癌症病人個案為藍本的癌症教育刊物，此刊物將由天地圖書負責印製。

(iii) Activities undertaken by members of the Cancer Comrades 「同路人」成員參與的活動

Date 日期:	11/05/2008	
Event 活動:	Chinese Music Concert sponsored by Si Yuan Foundation 思源基金會贊助的慈善中樂演奏會	
No. of Participants 參與人數:	Served as guest performer in the concert. About 1,300 participants attended the concert 在慈善中樂演奏會中擔任表演嘉賓。約有1,300名市民參與	
Member(s) 參與成員:	Ms. Cheung Pui-lan 張佩蘭女士	

Date 日期:	17/05/2008
Event 活動:	Attended the 12th Anniversary Celebration of 澳門愛心之友協進會 in Macau 赴澳門出席澳門愛心之友協進會的十二週年聚會
No. of Participants 參與人數:	About 250 participants including cancer patients, doctors, nurses, social workers, government officials of Macau as well as cancer support groups from Taiwan and Hong Kong had attended the celebration 約有250名包括癌症病人、醫生、護士、社工及當地的政府官員和來自台灣及本港的癌症支援組織參與聚會
Member(s) 參與成員:	Ms. Cheung Pui-lan 張佩蘭女士

(iv) 15th Anniversary Dinner 「同路人」第十五屆週年聚餐

The 15th anniversary dinner of Cancer Comrades was held on 23 August 2008 at Eaton Hotel. 146 participants included members of Cancer Comrades, staff & volunteers of the HKACS, cancer patients & their relatives, doctors, nurses, social workers and cancer groups from Macau and the Oncology Units of the major hospitals in Hong Kong got together to celebrate the joy of life and shared a lot of fun and laughs.

「同路人」第十五屆週年聚餐於本年8月23日在逸東酒店舉行。有146位參與者包括「同路人」成員、本會職員及義工、癌症患者及其家屬、醫生、護士、社工和來自澳門及本港主要醫院腫瘤部門的癌症病人互助組織聚首一堂慶祝歡愉的生活與分享無數的樂趣與歡欣。



August 2008 - Cancer Comrades 15th Annual Dinner: Dr. Ko Wing Man, Dr. Poon Yeuk Foo, Dr. Pamela Leung, Dr. Anne Lee, Dr. Tung Yuk, Ms. Betty Au and Ms. Iris Leung joined with 146 cancer patients, volunteers, doctors, nurse, social workers gathered together to celebrate the joy of life.

2008年8月—「同路人」十五周年聚餐：本會的高永文醫生、潘若英醫生、梁明娟醫生、李詠梅醫生、董煜醫生、區美如女士及梁小雲小姐與146名癌症病人、義工、醫生、護士和醫務社工等聚首一堂，共慶生命的喜悅。

CANCER RESEARCH 癌症研究

Membership of the Cancer Research Subcommittee 2007/08 2007/08 年度癌症研究委員會委員名單

Chairperson 主席:	Dr. Anne Lee Wing Mui	李詠梅醫生
Members 委員:	Dr. John Chan	陳國璋醫生
	Dr. C.K. Law	羅振基醫生

Membership of the Cancer Research Vetting Panel 2007/08 2007/08 年度癌症研究評審委員會委員名單

Chairperson 主席:	Dr. John Chan	陳國璋醫生
Members 委員:	Mr. Davie Au-yeung	歐陽贊邦先生
	Dr. Anne Lee Wing Mui	李詠梅醫生
	Mrs. Agnes Wong	黃馮玉棠女士
	Dr. Anthony Ying	應志浩醫生

This year the Subcommittee did not invite applications for cancer research grant in practice of limiting the annual cashflow to \$600,000 (Please refer to the table below - Cashflow for 2008). Therefore a new round invitation of applications will be carried out at the beginning of next year.

為了實踐本會對每年癌症研究資助上限 \$600,000 元的財務安排下，本會於今年並沒有邀請資助癌症研究的申請（請參閱下表 — 2008 年撥款一欄）。因此，新一輪的邀請資助癌症研究申請將於明年初進行。

Approved Research Grant's Disbursement 已審批的研究項目支出

No. 編號	Name of Applicant 申請人姓名	Study Title 研究項目名稱	Duration of Project 研究計劃為期	Total Grant approved 總撥款額	Cashflow for 2008 2008 年撥款	Accumulated Grant 累積資助
1	Dr. Larry Baum, Assistant Professor, Dept. of Medicine and Therapeutics, The Chinese University of Hong Kong 香港中文大學 內科及治療藥學系 包立怡助理教授	A novel cancer screening method using mismatch binding proteins to detect mutant, tumor-derived DNA in body fluids 在體液內用錯配識別蛋白檢查出 腫瘤衍生脫氧核糖核酸突變體 的一個創新癌細胞篩選方法	11/06 - 10/08 (2 years 為期2年)	\$150,000.00	\$0	\$150,000.00
2	Prof. Tang Leung-san, Nelson, Dept. of Chemical Pathology, The Chinese University of Hong Kong 香港中文大學 化學病理學系 鄧亮生教授	The Association of Pharmacogenetics and Chemotherapy-induced Toxicities in Breast Cancer Patients receiving Chemotherapy 乳腺癌的藥物遺傳學研究 — (化療導致的副作用與基因的關係)	07/06 - 06/08 (2 years 為期2年)	\$100,000.00	\$0	\$100,000.00

No. 編號	Name of Applicant 申請人姓名	Study Title 研究項目名稱	Duration of Project 研究計劃為期	Total Grant approved 總撥款額	Cashflow for 2008 2008年撥款	Accumulated Grant 累積資助
3	Dr. W.M. Lee, Anne, Cluster COS, Dept. of Clinical Oncology, PYNEH 東區尤德夫人那打素醫院臨 床腫瘤聯網及部門主管 李詠梅醫生 Dr. Roger Ngan, Consultant, Dept. of Clinical Oncology, QEH 伊利沙伯醫院臨床腫瘤部門 顧問醫生 顏繼昌醫生	Randomized trial to evaluate the therapeutic gain by changing the chemoradiotherapy from concurrent-adjuvant to induction- concurrent sequence, and the radiotherapy from conventional to accelerated fractionation for advanced nasopharyngeal carcinoma (NPC-0501 Trial) 在晚期鼻咽癌患者進行隨機測 試，透過將同步的輔助性藥物放 射治療轉變為同步的誘發性序列 藥物放射治療；及將慣常使用的放 射治療轉變為加速性分餾放射治 療，藉此評估轉變後在治療上的 得益(NPC-0501 測試)	01/06 – 12/12 (7 years 為期7年)	\$450,000.00 (for 3½ yrs. 共資助3½ 年)	\$145,200.00	\$435,600.00
4	Dr. Cheung Siu Tim Assistant Professor Dept. of Surgery, HKU 香港大學外科學系 助理教授 張兆恬博士	Combine targeted therapy with chemotherapy for liver cancer treatment 治療肝癌的化療合併導向式標 靶療法	10/07 - 09/08	\$200,000.00	\$100,000.00	\$200,000.00
5	Dr. Ng Kwok Chai, Kelvin Associate Consultant Dept. of Surgery, HKU 香港大學外科學系 吳國際顧問醫生	Prognostic significance of alpha-fetoprotein and albumin messenger RNA in patients with hepatocellular carcinoma treated by radiofrequency ablation: A prospective study 檢測甲胎蛋白和白蛋白資訊RNA 以預測射頻消融對肝癌患者的治 療效果	01/10/07 - 30/09/10	\$198,370.00	\$60,000.00	\$138,370.00
6	Dr. Michelle K.Y. Siu Research Assistant Professor Dept. of Pathology, HKU 香港大學病理系 助理教授(研究) 蕭君兒博士	p21-activated kinase 4: a prognostic and therapeutic target for ovarian carcinoma? p21-活化激酶 4:一個卵巢癌的預 後和治療指標?	01/10/07 - 30/09/08	\$296,137.00	\$214,707.00	\$296,137.00
Total 總數：				<u>\$1,394,507.00</u>	<u>\$519,907.00</u>	<u>\$1,320,107.00</u>

In February 2008, Prof. Yuen Po Wing, Clinical Professor of Torthinology, Division of Otorhinologygngology informed us that the research project on “The evaluation of the diagnostic efficacy of EBV DNA and RNA in the nasopharyngeal brushing of patients at risk of nasopharyngeal carcinoma” had to be aborted due to his resignation from his post. The Subcommittee has decided that his grant of \$200,000 be carried forward to the next round application.

本年二月香港大學外科學系耳鼻喉科袁寶榮教授知會本會，由於他的離任而必須終止進行他於2007年向本會申請資助癌症研究－「研究鼻咽癌高危病人鼻咽刷子樣本EB病毒去氧核糖核酸和核糖核酸的鼻咽癌診斷準確度」的項目。經委員會商議後，該為數港幣200,000元的撥款將撥歸新一輪資助癌症研究申請之用。

Reports on the cancer research projects 受資助癌症研究計劃的報告

1

Project title 項目名稱:	2008 Progress Report On A Novel Cancer Screening Method Using Mismatch Binding Proteins To Detect Mutant, Tumor-Derived DNA In Body Fluids 2008 年進度報告關於一個新穎的癌症篩選方法，使用錯配連結蛋白去檢測在體液裡腫瘤導出的突變DNA
Principal Investigator 主要研究人員:	Associate Professor Larry Baum Chinese University of Hong Kong Shatin, Hong Kong 包立怡助理教授香港, 沙田, 香港中文大學內科及藥物治療學系

I thank the Hong Kong Anti-Cancer Society for their generous support of this project via a Cancer Research Grant of HK\$150,000 which began 1/11/06 and will end 31/10/08. Cancer is caused by mutations, which can be found only in cancerous cells. To detect cancer early, we aimed to develop a method to screen human liquid or waste such as blood or feces for mutant DNA shed from cancer cells, to allow pre-symptomatic cancer screening and thus surgical or other treatment with a much higher cure rate than is now possible.

The method entailed extracting DNA of target genes from human fluids or feces, heating and cooling to re-form DNA duplexes, and enriching for heteroduplexes—DNA sequences that are mismatched due to a mutation—to allow detection of mutations by sequencing. Immobilized mismatch binding protein can perform this enrichment by binding DNA heteroduplexes while allowing other DNA to be washed away. To test the method, short, single strands of synthetic DNA, with or without mutations, were combined to form homo- or heteroduplexes that were then mixed at low ratios of hetero- to homoduplexes and enriched for heteroduplexes. A single base deletion was enriched by a factor of 29, and a mismatch was enriched by a factor of 2.

Next, we tested the method on PCR products, which are longer, double strands of DNA that are amplified from purified, human DNA. However, no enrichment was achieved. One possible cause of failure is the presence of artifactual mismatches in the PCR primers, which are short strands of synthetic DNA used to initiate amplification in PCR. For a substantial minority or even a majority of individual primer molecules, at least one synthetic DNA error may occur somewhere within each molecule. These errors act like mutations, forming mismatches that cause the duplex to be enriched. These erroneously-enriched duplexes dilute the enrichment of mutations within the targeted region, perhaps making them undetectable. To avoid this potential problem, we designed PCR primers with a special DNA sequence that attracts a DNA-cutting enzyme (Mme I) to cut off the entire primer region of the PCR product after amplification has been completed. Another possible source of artifactual mismatches is inaccurate amplification in PCR; we reduced this potential problem by using a high-fidelity PCR enzyme (Pfx) for amplification. However, both of these measures failed to lead to enrichment of PCR products.

我感謝香港防癌會對這個科研項目慷慨的支持。此科研項目得到該會一份於1/11/06開始並將於31/10/08結束的HK\$150,000的癌症研究資助。基因突變是癌症的成因，並只能在癌細胞裡被找到。為及早檢測癌症，我們打算研發一種方法去篩選人的液體或廢物，譬如血液或糞便，從癌細胞散發出的突變的脫氧核糖核酸（DNA），允許症狀發生前的癌症篩選並因此使外科或其他治療的痊癒率可以比現在更高。

方法需要從人的分泌液或糞便提取目標基因的DNA，加熱和冷卻去重組DNA雙鏈，並且豐富異源雙鏈——由於一個突變而產生的DNA序列錯配——允許以排序作突變的檢測。被固定的錯配連結蛋白能通過連結DNA異源雙鏈同時容許其他DNA被沖走，執行這豐富。為了測試方法，短小的，合成DNA單鏈，有或沒有突變，被合併組成同源或異源雙鏈，接著以低比率的異源比同源雙鏈被混和及豐富為異源雙鏈。一個單鹼基缺失被豐富了29倍，並且一個錯配被豐富了2倍。

接著，我們測試了方法在聚合酶連鎖反應（PCR）產品上，是更長的，DNA雙鏈，增殖自己純化的，人的DNA。但是，豐富未能實現。失敗的一個可能的起因是人為構造的錯配出現在PCR引子，短小的合成DNA鏈，被用於在PCR中引發增殖作用。在大體上的少數或更大多數個別的引子分子，最少一合成DNA錯誤可以發生在各個分子之內的某處。這些錯誤表現如突變，形成導致雙鏈被豐富的錯配。這些錯誤地被豐富的雙鏈稀釋在目標區域之內突變的豐富，或許使它們變得探測不到的。為了避免這個潛在的問題，我們設計了有一特別DNA序列的PCR引子，以吸引一個DNA切割酵素（MmeI）去切除在增殖作用完成後PCR產品的整個引子區域。另一可能的人為構造錯配的來源是在PCR中不精確的增殖作用；我們藉在增殖作用方面使用高保真度的PCR酵素（Pfx）減少這個潛在的問題。但是，這兩個措施不能導致PCR產品的豐富。

Perhaps some component of the PCR reaction inhibits enrichment. To examine this, we performed enrichment with synthetic DNA to which was added either PCR reaction chemicals or only water. Enrichment occurred in both conditions, thus the PCR chemicals were not inhibiting enrichment.

Since we could not identify the reason PCR inhibited enrichment, we have started to pursue an alternate approach which avoids PCR before enrichment, instead using hybridization to extract target genes from human DNA, then forming duplexes and enriching for mismatches, and finally amplifying by PCR. The procedure is as follows:

1. Purify genomic DNA from tissue
2. Cut with restriction enzyme to produce DNA fragments of reasonable size
3. Purify desired sequence using immobilized DNA probes: both sense and antisense
4. Melt DNA off probes and isolate it
5. Melt purified DNA and allow sense to hybridize with antisense
6. Enrich mismatches using immobilized mismatch binding protein as before
7. Amplify enriched DNA by PCR
8. Sequence to observe degree of enrichment

We do not yet have results from this approach, but we will continue this research after the end of the grant period.

或許PCR反應的某些成分抑制豐富。為了調查這個，我們加了PCR反應中的化學物或只有水到合成DNA，執行了豐富。豐富發生了在兩個環境，因此PCR反應中的化學物沒有抑制豐富。

我們的計劃是下一步設計PCR引子以一個錯配在他們的序列，執行非突變的人的DNA的PCR增殖作用，和然後測試引子錯配的豐富是否能夠發生。一個代替方法是避免在豐富前的PCR，反而使用雜交作用去從人的DNA提取目標基因，然後形成雙鏈和豐富錯配，及最後以PCR增殖。具體操作步驟如下：

1. 從組織中提取基因組DNA。
2. 用限制性切酶消化DNA,獲得合適大小合適的DNA片斷。
3. 利用固定化的DNA探針純化目的片斷（所有的正義DNA和反義DNA）
4. 從探針上洗脫并純化目的DNA片段。
5. 溶解純化后的DNA，使正義和反義DNA雜交。
6. 利用固化的錯配結合蛋白富集錯配序列（同前面的方法）。
7. 用PCR方法擴增富集的DNA。
8. 測序，並獲得濃縮度。

我們還沒有利用此方法獲得獲得最終的實驗結果，但是在該項資助基金結束後我們依然會繼續該項試驗。

2	Project title 項目名稱:	The Association of Pharmacogenetics and Chemotherapy-Induced Toxicities in Breast Cancer Patients Receiving Chemotherapy 乳腺癌的藥物遺傳學研究－(化療導致的副作用與基因的關係)
	Principal Investigator 主要研究人員:	Prof Tang, Leung Sang Nelson, Department of Chemical Pathology, The Chinese University of Hong Kong 香港中文大學化學病理學系鄧亮生教授
	Co-investigator 共同研究人員:	Prof Winnie Yeo, Associate Professor, Department of Chemical Pathology, The Chinese University of Hong Kong 香港中文大學腫瘤學系楊明明副教授

“Summary of the project” 「項目摘要」

Chemotherapy is a main stage treatment in many breast cancer patients. However, such treatment is associated with toxicity leading to side effects including symptoms of vomiting. Anemia (low haemoglobin), and pancytopenia (low white blood cells) are important side effects due to toxicity of chemotherapy to the bone marrow. Presently, it is not able to predict which patient will have more severe toxic effect and therefore, all patients receive the same empirical dosage of cytotoxic drugs.

These cytotoxic drugs are cleared or metabolised by the body by groups of enzymes. It is recognised that genetic variations in single base of the genes of these enzymes could affect the ability of the body to metabolize the cytotoxic drugs. Therefore, the purpose of this study is to analysis the genetic variations in these enzymes and their inducer genes in Hong Kong Chinese and their association with clinical toxicity after chemotherapy in breast cancer patients. In the long term, the goal of this and future studies of this kind is to enable prediction of body response to drug and therefore, patients will be given personalised medicine, that is dosage or regimen of drug tailor-made to persons' body/genetic makeup.

對於許多乳腺癌患者來說，化療是一種主要的治療方法。然而，這種療法會產生副作用，對骨髓的重要副作用是貧血（血紅蛋白低）和全血細胞減少症（白細胞少）。目前還不能預測對患者產生毒副作用的輕重程度，因此所有化療患者在服用化療藥物時都服用同樣的劑量。這些化療藥物在人體內通過酶群進行代謝或清除。現在已經知道這些藥物代謝酶基因的遺傳變異能夠影響人體代謝化療藥物能力和副作用的輕重程度。因此，本研究旨在分析香港的中國人的藥物代謝酶基因的遺傳變異，以及分析這些遺傳變異與乳腺癌患者化療後的臨床毒副反應的相關性。從長遠來看，本研究 and 未來此類研究的目標就是預測人體對藥物的反應程度，並進而實現患者用藥的個體化，也就是根據患者個人的身體狀況和遺傳信息來給患者配藥並確定相應的劑量。

Report of Progress (up to June 2008) 報告進展情況（截至2008年6月）

The project has been commenced since 1 June 2006.

本研究計畫始於（2006年6月1日）。

Up to June 2008, we have completed follow up of 80 patients during their chemotherapy course which consists of 4 cycles of treatment. In our recent study, we investigated the association of a functional SNP in PTGS-2 (encoding for the COX-2, cyclooxygenase-2) and clinically significant neutropenia after chemotherapy among breast cancer patients because COX-2 regulate the expression of MDR-1 (P-glycoprotein) which affect cellular transport of many cytotoxic drugs and thus, their cytotoxicity. COX-2 is the inducible isoenzyme for which we have previously identified a putative functional SNP in the coding gene for COX-2, PTGS-2. Eighty Chinese female breast cancer patients were studied and monitor throughout the cycles of treatment by a standard doxorubicin-cyclophosphamide regimen. A 3-UTR SNP (rs5275, Ex10+837 T>C) in the PTGS-2 gene was genotyped by PCR-RFLP as described previously. In the study cohort, 16% of patients developed clinically significant neutropenia requiring a change of treatment cycle/regimen, 12 of them were homozygote TT genotype while 43 out of 60 of those not affected were homozygote. The genotype of patients with clinically significant neutropenia were compared to a sample of 244 population controls and the allelic frequencies of T allele showed a borderline significant difference (0.96 in neutropenia group and 0.81 in population, $p=0.06$).

在我們最近的研究中，檢查了PTGS - 2（環氧化酶第2）基因的單核苷酸多態性和乳腺癌患者化療後嗜中性白血球減少症的關係。環氧化酶第2有調節MDR - 1（P-糖蛋白）的作用，影響許多藥物在細胞的作用，和其細胞毒性。COX - 2是誘導酶，我們先前已經確定了COX - 2的單核苷酸多態性基因編碼。我們研究了80位中國女性乳腺癌患者和監測整個化療週期的細胞毒性，位於PTGS - 2（環氧化酶第2）基因 3非編碼區有一個單核苷酸多態性（rs5275）

16 %的病人有中性粒細胞減少症，需要改變的治療週期/方案，其中12個是純合子TT基因型，我們也分析244人口對照組的”T”等位的基因頻率，發現”T”等位在中性粒細胞減少症組比較常見（“T”等位基因頻率:在中性粒細胞減少症組為0.96和人口對照組為0.81， p 值0.06）。

Preliminary findings 初步結果

This 3-UTR SNP was a potential functional SNP located within a region which had been shown to influence mRNA stability. The T allele had been implicated for regulation of COX-2 activity. It is postulated that prostaglandin metabolism may contribute to the growing dimension in pharmacogenetics of chemotherapy toxicity.

These results have been presented in an abstract in the XX International Congress of Genetics in Berlin, Germany (July 12 – 17, 2008).

這3非編碼區單核苷酸多態性是一個有潛在的功能的單核苷酸多態性，它設在一個有影響mRNA的穩定性的位置。T等位基因有調節COX - 2的活性的作用。

這結果已經在德國柏林國際遺傳學大會作簡報。

- | | |
|----------|--|
| 3 | <p>Project title 項目名稱: A proposal to determine the therapeutic gain by induction-concurrent chemoradiation over concurrent-adjuvant chemoradiation and the benefit of adjuvant chemotherapy in NPC patients with residual EBV DNA following primary treatment
判斷「引導－同步化療」對比「同步－輔助化療」所獲得的療效以及對接受過初步放射治療後有殘餘EB病毒DNA病人施以輔助化療的效益的計劃書</p> <p>Principal Investigator 主要研究人員: Dr Anne Lee Wing-mui for Hong Kong Nasopharyngeal Cancer Study Group
香港鼻咽癌研究小組李詠梅醫生</p> |
|----------|--|

Two prospective randomized multi-center studies 兩項前瞻性、隨機、多中心研究

Nasopharyngeal carcinoma is the 7th commonest cancer in Hong Kong: 944 new cases were detected in 2005. As people at the prime of their life are mostly affected (peak age-specific incidence being 30-70 years), the impact is especially devastating. Recent researches in Hong Kong have shown that chemotherapy in addition to standard radiotherapy improves treatment outcomes, particularly for those patients presented with advanced disease. With these encouraging findings, two randomized studies (0501 and 0502) were initiated in 2005 under the sponsorship by the Hong Kong Anti-Cancer Society. The purposes of these studies are to determine the optimal way of delivering chemotherapy and radiotherapy; and whether additional chemotherapy could help those patients who fail to achieve normalization of EBV DNA level after initial treatment. All six oncology centers in Hong Kong are actively participating in these studies; with additional contribution from Sun Yat-sen Cancer center at GuangZhou. Recruitment to these studies is still ongoing and about 260 patients have been successfully randomized in 0501 trial; and another 25 patients in 0502 trial. We expect that enrollment would be completed by the end of 2013 and interim analyses are currently underway.

鼻咽癌是香港第七位的常見癌症，於2005年共有944宗新症，其中三十至七十歲的病發率最高，對人生全盛期的影響尤為嚴重。最近香港有研究指出，標準放射治療加上化療可以改善療效，而對晚期鼻咽癌的病人尤為顯著。根據這些結果，在香港防癌會的贊助下，於2005年開始了兩項關於鼻咽癌的隨機研究（0501及0502），目的是找出給予化療及放射治療的最理想方法；以及決定對在接受初步治療後EB病毒DNA水平未能回到正常的病人，加入化療能否有所幫助。香港六個腫瘤中心及廣州中山大學腫瘤防治中心均參與這兩項研究，0501和0502研究現正分別約有260位和25位病人參加，並預計登記程序會於2013年年底結束，而中期分析現正進行。

- | | |
|----------|---|
| 4 | <p>Project title 項目名稱: Combine targeted therapy with chemotherapy for liver cancer treatment
治療肝癌的化療合併導向式標靶療法</p> <p>Investigator研究人員: Dr S.T. Cheung, Assistant Professor, Department of Surgery, The Hong Kong University of Hong Kong
香港大學外科學系助理教授張兆恬博士</p> <p>Prof S.T. Fan, Department of Surgery, The Hong Kong University of Hong Kong
香港大學外科學系范上達教授</p> |
|----------|---|

First Progress Report 首份進度報告

Background 背景

Liver cancer is the second major cause of cancer death in China. Surgical resection is the mainstay of curative treatment. However, liver cancer is usually diagnosed at an advanced stage and so precludes curative treatment. Chemotherapy remains the principal approach in treating unresectable HCC. However, both single-agent chemotherapy and combination chemotherapy have shown marginal efficacy. A new treatment strategy is essential to sensitize the cancer cells to chemotherapeutic agents.

We have demonstrated the overexpression of granulin-epithelin precursor (GEP, also called progranulin, acrogranin, or PC-derived growth factor) in primary liver cancer, and that GEP is a therapeutic target for liver cancer treatment. We hypothesize that GEP-targeted therapy will enhance the sensitivity of hepatoma cells to chemotoxic agents. In a pilot study, we demonstrated that GEP-targeted therapy in combination with cisplatin could further enhance treatment efficacy. We propose further pre-clinical studies to examine the optimal regimen for cancer treatment. Specific Aim 1: To examine the functional effect of anti-GEP mAb in combination with chemotoxic agents. Specific Aim 2: To evaluate the treatment efficacy of anti-GEP mAb treatment in combination with chemotoxic agents in mouse model. The study will improve the treatment strategies for liver cancer.

肝癌是中國的第二號癌症殺手。醫治肝癌，手術切除是最主要的方法。然而，肝癌往往於晚期才被診斷出來，以手術切除來醫治末期肝癌並不可行。要治理不能切除的肝腫瘤，化療是最主要的方法。可惜，不論是單藥化療抑或是組合化療，皆成效不彰。是以，一種加強癌細胞對化療藥物的反應的肝癌新療法，至為必要。

我們曾經揭示原發性肝癌中「上皮素粒素前體」（又稱「畸胎瘤細胞源性生長因子」）的過度表達，亦揭示了這種前體可以作為治療肝癌的靶點。我們假設以「上皮素粒素前體」為標靶的治療可以提高肝癌細胞對化學毒劑的敏感度，而在一試點研究中，更展示了在「上皮素粒素前體標靶治療」中使用順鉑，可以進一步提升療效。我們倡議更深入的臨床前研究，為癌病的治療尋覓最佳的方法，目標有二：第一，測驗化學毒劑合以「抗上皮素粒素前體單株抗體」後的功能效果；第二，以鼠模型來評估化學毒劑合以「抗上皮素粒素前體單株抗體」的療效。這項研究有望改善治療肝癌的策略。

Research Progress 研究進程

- (1) Neutralization of GEP by anti-GEP mAb further enhanced the anti-proliferative effect induced by conventional chemotherapeutic agents
以「抗上皮素粒素前體單株抗體」中和「上皮素粒素前體」，進一步加強了傳統化療藥物所帶來的抗增殖作用：

Different classes of drug compounds were examined, including doxorubicin (anti-neoplastic antibiotic), cisplatin (alkylating agent) and 5-Fluorouracil (5-FU) (anti-metabolite). Low dose of chemotherapeutic agents inhibited the proliferation of Hep3B cells by MTT assay (Figure 1). Importantly, combination of low-dose chemo drugs and anti-GEP mAb further enhanced the anti-proliferative effect compared to single-agent treatment.

我們測試了不同類別的複合藥，包括阿黴素(抗腫瘤抗生素)、順鉑(烷化劑)和五氟脲嘧啶(抗代謝物)。在MTT比色法中，低劑量的化療藥物抑制了Hep3B細胞的增殖(圖一)。重要的是，比起單藥治療，低劑量化療藥合以「抗上皮素粒素前體單株抗體」，進一步增強了抗增殖作用。

- (2) Neutralization of GEP by anti-GEP mAb further enhanced the apoptotic effect induced by chemotherapeutic agents
以「抗上皮素粒素前體單株抗體」中和「上皮素粒素前體」，進一步加強了化療藥物所帶來的凋亡作用

Tumor growth is an imbalance of cell proliferation and cell death. Thus, the role of anti-GEP mAb in cell apoptosis would need to be elucidated. Anti-GEP mAb treatment alone at 100ug/ml for 24 hours demonstrated no effect on cell apoptosis compared to control treatment (saline control or non-specific mouse IgG control) as examined by flow cytometry. The in vitro observation was consistent with our earlier in vivo study that anti-GEP mAb treatment on Hep3B xenograft in mouse model revealed only decreased proliferation but not significant change in apoptosis by TUNEL staining [Ref 1]. Nonetheless, combination of anti-GEP mAb at 100ug/ml and cisplatin at 4ug/ml demonstrated synergistic effect on induction of apoptosis (28.4%) compared to single-agent treatment (6.7% and 15.8%, respectively) (Figure 2). We will continue the pre-clinical studies to examine the optimal regimen for liver cancer treatment.

腫瘤的生長是細胞增殖與細胞死亡之間的失衡，故此，「抗上皮素粒素前體單株抗體」在細胞凋亡中所扮演的角色，尤需闡明。我們以100ug/ml的「抗上皮素粒素前體單株抗體」作24小時的單藥治療，流式細胞術所測定的結果顯示，比諸兩個對照組（生理鹽水組、非特异性小鼠免疫球蛋白G組），這項治療對細胞凋亡不起任何作用。這次活體外的觀察所得，與我們之前的鼠模型活體研究的TUNEL染色法檢測結果一致，就是「抗上皮素粒素前體單株抗體治療」可以削弱Hep3B移植瘤的增殖，但對於細胞凋亡的影響卻並不顯著（參考一）。而在另一項實驗中，100ug/ml的「抗上皮素粒素前體單株抗體」輔以4ug/ml的順鉑，對誘發細胞凋亡產生協同效應（凋亡率為28.4%），療效遠勝兩個單藥治療對照組（凋亡率分別為6.7%和15.8%）（圖二）。我們會繼續這些臨床前研究，務求尋找出治療肝癌的最佳方法。

Figure 1 圖一




Figure 1 Neutralization of GEP by anti-GEP mAb A23 further enhanced the anti-proliferative effect induced by conventional chemo-drugs. a, Doxorubicin at 0.025ug/ml in combination with anti-GEP mAb at 100ug/ml further inhibited the cancer cell proliferation compared to single agent treatment. b, Cisplatin at 0.5ug/ml in combination with anti-GEP mAb at 100ug/ml further inhibited proliferation compared to single agent treatment. c, 5-FU at 0.25ug/ml in combination with anti-GEP mAb at 100ug/ml further enhanced the anti-proliferative effect compared to single agent treatment.

圖一 以「抗上皮素顆粒素前體單株抗體」中和「上皮素顆粒素前體」，進一步加強了傳統化療藥物所帶來的抗增殖作用。相比單藥治療，a 100ug/ml的「抗上皮素顆粒素前體單株抗體」輔以0.025/ml的阿黴素，更加抑制了癌細胞的增殖；b 100ug/ml的「抗上皮素顆粒素前體單株抗體」輔以0.5ug/ml的順鉑，更加抑制了細胞的增殖；c 100ug/ml的「抗上皮素顆粒素前體單株抗體」輔以0.25ug/ml的五氟尿嘧啶，強化了抗增殖作用。

Figure 2 圖二




Figure 2 Neutralization of GEP by anti-GEP mAb further enhanced the apoptotic effect induced by cisplatin in Hep3B cells. Anti-GEP mAb alone has no effect on cell apoptosis compared to control treatment (saline control or non-specific mouse 1gG control), while in combination with cisplatin could sensitize the cells to undergo apoptosis compared to single agent treatment.

圖二 以「抗上皮素顆粒素前體單株抗體」中和「上皮素顆粒素前體」，進一步加強了Hep3B細胞中由順鉑所引起的凋亡作用。相比單藥治療的對照組（生理鹽水組、非特异性小鼠免疫球蛋白G組），單純的「抗上皮素顆粒素前體單株抗體」對細胞凋亡不起作用，一旦輔以順鉑，則引發細胞凋亡。

Research output 研究成果

Invited Lecture. Cheung ST (presenting author) and Fan ST. From Gene Expression Profile to Identification of Molecular Target Granulin-Epithelin Precursor for Liver Cancer. The Ehrlich II – 2nd World Conference on Magic Bullets. Oct 3-5, 2008. Nuremberg, Germany.

Reference 參考文獻

Ho JC, Ip YC, Cheung ST (correspondence), Lee YT, Chan KF, Wong SY, Fan ST. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 2008; 47:1524-1532.

5

Project title 項目名稱:	Prognostic significance of alpha-fetoprotein and albumin messenger RNA in patients with hepatocellular carcinoma treated by radiofrequency ablation: A prospective study 檢測甲胎蛋白和白蛋白資訊RNA以預測射頻消融對肝癌患者的治療效果
Principal Investigator 主要研究人員:	NG Kwok Chai, Kelvin/Consultant for Department of Surgery, the University of Hong Kong 香港大學外科學系顧問醫生吳國際
Co-investigator(s) 副研究員:	Yang Zhen Fan, Assistant Professor, Poon T.P. Ronnie, Clinical Professor Fan Sheung Tat, Professor for Department of Surgery, The University of Hong Kong 香港大學外科學系助理教授楊振帆 香港大學外科學系潘冬平教授 香港大學外科學系范上達教授

1. Project Objectives 目的

1.1 Objectives as per original application 原課題目的

To evaluate the prognostic value of circulating AFP and albumin mRNA levels in patients with HCC treated by RFA

研究血液甲胎蛋白和白蛋白資訊RNA在預測射頻消融後肝癌患者預後的作用

1.2 Revised objectives 修改後的課題目的

To investigate the prognostic value of circulating HIF-1 α and HIF-2 α mRNA levels in patients with HCC treated by RFA

研究血液缺氧誘導因數1 α 和2 α 資訊RNA在預測射頻消融後肝癌患者預後的作用

Reasons for the change

修改原因

Detection sensitivity of circulating AFP and albumin mRNA was not satisfactory.

檢測血液甲胎蛋白和白蛋白資訊RNA的敏感性不夠高

2. Research Activities 研究活動

2.1 Research activities in relation to the project objectives that were carried out 已進行的研究活動

We have collected 76 blood samples from 38 HCC patients with RFA treatment, and 10 blood samples from normal subjects and cirrhosis controls, respectively. HCC patients have been followed-up for more than 6 years.

我們已經從38個肝癌患者中收集了76個血液標本（一半來自於射頻治療前，一半來自於射頻治療後一周）。另外，我們也分別從正常和肝硬化對照組收集了10個血液標本。最長的肝癌病人隨訪期長達6年。

2.2 Areas addressed and results expected during this reporting period 本年度實驗結果

Albumin was detectable in 23 out of 76 blood samples collected from HCC patients, 1 blood sample from cirrhosis control and 4 blood samples from liver donors. AFP was only detectable in 2 blood samples from HCC patients, and none in normal and cirrhosis controls. Since the current protocol using either AFP or Albumin as parameters had low sensitivity, we switched to hypoxia inducible factor-1 α (HIF-1 α) and -2 α (HIF-2 α), two transcriptional factors that modulate cancer stem cell gene expression, to investigate whether these two genes could more sensitively represent circulating cancer cells/cancer stem cells. A significantly higher sensitivity was observed when HIF-1 α and HIF-2 α were used for detection. In addition, mRNA level of HIF-2 α was higher in blood pellet collected from HCC patients than those from cirrhosis and normal controls.

在76個肝癌，1個肝硬化和4個正常血液標本中，23個標本檢測到陽性白蛋白資訊RNA。甲胎蛋白AFP資訊RNA只在2個肝癌血液標本中檢測到。我們總結使用甲胎蛋白和白蛋白資訊RNA作為檢測指標的敏感性不夠高。因此，我們轉而採用缺氧誘導因數1 α 和2 α 資訊RNA作為檢測指標以提高敏感性。這兩個轉錄因數被發現具有調節癌症幹細胞基因的功能。這一改進顯著提高檢測敏感性。並且，血液中缺氧誘導因數2 α 資訊RNA在肝癌病人中的表達明顯高於肝硬化和正常對照組。

2.3 Areas to be addressed and results expected in the next reporting period 下一年度需要解決的問題

During the next reporting period, we plan to analyze the correlation between circulating HIF-1 α and HIF-2 α levels and prognosis of HCC patients with RFA treatment. In addition, we have been prospectively collecting blood samples from another HCC patient cohort to validate the available data. We are planning to submit the findings of current study to next year's American Association for Cancer Research Annual Meeting.

我們計畫在下一年度進一步分析血液缺氧誘導因數1 α 和2 α 資訊RNA表達與射頻消融後肝癌病人預後之間的關聯。除此之外，我們也前瞻性地從另外一組肝癌病人中收集血液標本以驗證本年度的發現。最後，我們計畫以本實驗發現參加下一年美國癌症協會年會。

6	Project title 項目名稱: p21-activated kinase 4: a prognostic and therapeutic target for ovarian carcinoma? p21活化蛋白激酶 4 (Pak4): 卵巢癌預後和治療的靶向?
	Principal Investigator 主要研究人員: Dr Michelle K. Y. Siu, Research Assistant Professor, Department of Pathology, The University of Hong Kong 香港大學病理科研究助理教授蕭君兒博士
	Co-investigator(s) 副研究員: Prof Annie N.Y. Cheung, Departments of Pathology, The University of Hong Kong 香港大學病理科張雅賢教授 Prof Hextan Y.S. Ngan, Obstetrics and Gynaecology, The University of Hong Kong 香港大學婦產科顏婉嫦教授

Project Objectives 課題目的

Ovarian cancer is a lethal gynecological malignancy. To improve patients' survival, it is important to identify novel prognostic and therapeutic targets. In this study, the role of p21-activated kinase 4 (Pak4) in ovarian cancer progression was investigated. We demonstrate a significant association between increased expression of Pak4 and its activated form, phosphorylated (p)-Pak4 Ser474, with metastasis of ovarian cancers, shorter overall and disease-free survival, advanced stage and high grade cancers, serous/clear cell histological subtypes and reduced chemosensitivity. Pak4 overexpression was also observed in ovarian cancer cell lines. Pak4 and p-Pak4 expression were detected both in the nucleus and cytoplasm of ovarian cancer cells, in vitro as well as in vivo. Stable knockdown of Pak4 in ovarian cancer cell lines led to reduced cell migration and invasion along with reduced c-Src and ERK1/2 activation and decreased matrix metalloproteinase 2 expression, demonstrating a physiological link between Pak4, c-Src, ERK1/2 and MMP2. Conversely, ectopic Pak4 overexpression enhanced cell migration and invasion in a kinase-dependent manner. This is the first report revealing the association between Pak4 and important clinicopathologic parameters, suggesting Pak4 to be a significant prognostic marker and potential therapeutic molecular target in ovarian cancer.

卵巢癌是致命的婦科惡性腫瘤。辨識新的預後和治療的靶向對提高病人的生存率非常重要。在此，我們研究了Pak4在卵巢癌進展過程中的作用。我們證實增加Pak4和它的活化形式(磷酸化)的表達與卵巢癌的轉移、總體存活率和無瘤存活率的降低、晚期癌和高級別癌、漿液性癌/透明細胞癌亞型及低化學敏感性顯著相關。在卵巢癌細胞系中同樣發現Pak4增加表達。體內和體外試驗中均發現在卵巢癌細胞核和細胞質中都有Pak4和磷酸化Pak4的表達。在卵巢癌細胞系中穩定剔除Pak4的表達能導致細胞遷移和侵襲降低，活性c-Src、活性ERK 1/2和MMP2的表達亦同時降低，證明Pak4、c-Src、ERK 1/2和MMP2之間有生理學關係。相反，在異常高表達的Pak4通過磷酸化能提高細胞遷移和侵襲。本研究最先報道Pak4和臨床病理學參數之間的相關作用，認為Pak4可作為卵巢癌中重要的預後指標和潛在的治療分子靶向。

Nasopharyngeal Carcinoma (NPC) 鼻咽癌

The research on Nasopharyngeal Carcinoma (NPC) is led by Dr. Law Chun-key of the Department of Clinical Oncology of Queen Elizabeth Hospital and financially assisted by our Society.

本會繼續財政資助由伊利沙伯醫院臨床腫瘤科部門主管羅振基醫生領導進行的鼻咽癌研究。

(A) Inflammation related gene discovery in NPC patients treated with an anti-inflammatory drug – Celecoxib 在使用CELECOXIB 抗炎藥治療鼻咽癌病人中發現與炎症有關的基因

We continue to perform gene chip analysis in the nasopharyngeal tissues obtained from a cohort of nasopharyngeal cancer (NPC) patients before and after treatment by an anti-inflammation drug, Celebrex followed by radiotherapy with or without chemotherapy in collaboration with University of Hong Kong. More cases were studied and RNA was extracted from the cancer and normal tissues. It was then amplified to generate sufficient quantity of cDNA for gene chip experiment. The cDNA was labeled with two fluorescent dyes, Cy5 and Cy3 for genetic hybridization experiments onto gene chip. More than half of the cases were performed. Interim analysis of the results will be carried out in this larger number of cohort to select reliable gene markers correlating with this malignancy and treatment so that further applications in diagnosis, prognostication and treatment can be explored. Subsequent RT-PCR experiments will be performed to confirm the tumor and treatment specificity of these gene markers. Functional analyses will also be carried out to examine the roles these gene markers play in the carcinogenesis process of NPC.

研究小組聯同香港大學繼續進行基因晶片分析，包括於鼻咽癌病人使用抗炎藥物前，及使用抗炎藥物後，電療後及或化療後抽取鼻咽組織作分析。從不同的個案中分別從正常細胞及癌細胞中抽出核糖核酸(RNA)，並增強致產生充足的補充脫氧核糖核酸(cDNA)以進行基因晶片分析，再分別用兩種螢光染體Cy5 及Cy3在過半數的病人案例的基因晶片上作基因染交實驗，篩選出惡性腫瘤及治療中可靠的基因標識，進深探究於診斷、徵兆及治療的應用，並會發表中期報告。隨後用複本酶鏈反應技術(RT-PCR)驗試腫瘤及治療基因標識的具體性；同時亦會就基因標識作功能性分析以解構基因標識在鼻咽癌的形成過程中所扮演的角色。

(B) Identification of protein markers by protein chip array profiling 蛋白質晶片排列確認腫瘤蛋白標識

Two areas of proteomics work were being studied with one area in NPC and the other in lymphoma. Proteomic analyses of chemotherapy related peptide markers in NPC are being carried out in this project. A number of peptide markers which are associated with chemo-response have been found. A manuscript is under preparation to report this finding. More and more studies indicate that cancer is a kind of chronic inflammation and cancer patients share many inflammatory proteins or peptides with patients who suffer from bacterial or viral infection and presented with inflammation symptoms. We have performed serum proteomics analysis in lymphoma and SARS patients. In this study, we compare the proteomic data generated from the lymphoma patients and another set of data generated from the SARS patients with severe inflammation. We aim to find specific set of markers associated with lymphoma and inflammation diseases. Markers common to both were also examined to try to delineate the carcinogenesis process involving chronic inflammation. A manuscript is under preparation to report this finding.

小組繼續就鼻咽癌及淋巴瘤進行蛋白組分析研究，並從鼻咽癌化療中相關的月太標識作蛋白組分析。過程中發現為數不少的肽標識與化療反應有關聯，我們就是次發現準備報告稿。越來越多研究顯示癌病類屬慢性炎症，很多癌病人和患有細菌或病毒感染病人同時發現有炎症性蛋白或月太。我們從淋巴瘤及非典型肺炎病人做血清蛋白組分析，將兩組病人的蛋白組數據作比較，目的是要從淋巴瘤及炎症疾病中找出明確的標識，再細查相同的標識并鉤劃出致癌過程中牽涉到的慢性感染，我們亦會就以上的發現準備文字報告本。

(C) CpG island microarray analysis of cancer CpG島狀物微型基因晶片分析癌症

DNA methylation of tumor suppressor genes is a frequent event occurring in cancer patients. Using high density CpG island microarray technology, we examine the methylation status in 244,000 gene promoters. A large battery of methylated genes were found. By means of methylated specific PCR and bisulphite sequencing technologies, we are now confirming the results. The transcript expression of these genes are also examined by RT-PCR. We will report the findings of this study when the quantities of the methylated genes found reach a substantial level and their methylation status is confirmed.

腫瘤抑制基因脫氧核糖核酸甲基化慣常在癌症病人中發生。利用高密度CpG島狀物微型基因晶片技術，查看244,000促進基因的甲基化並發現一連串甲基化基因，運用甲基化酶鏈反應及重亞硫酸鹽核糖核酸序列技術確認了是項查驗。這連串的基因再用複本酶鏈反應技術查驗，至基甲化基因達至一個可觀的水平才可確定基甲化的狀態，我們亦會將此研究的結果公佈。

Publications of Radiobiology & Cancer Research Unit 放射生物學部及癌症研究小組刊印 / 發表的文章

1. Yip TTC, Ngan RKC, Cho WCS, Law SCK. Proteomics approach in cancer diagnosis - Nasopharyngeal Cancer as a model. Biomedicine & Pharmacotherapy (Invited Review (2007).
2. Cho WCS, Yip TTC, Ngan RKC, Yip TT, Yip C, Chan JWM, Tsang DNC, Chan JKC, Cheng WW, Ma WWS, Lim CKP, Lim WWL, Law SCK. Differential and common serum proteomics in cancer and inflammation disease: A comparative analysis in lymphoma and SARS using Protein Chip array profiling. Proceedings of the Annual Meeting of the American Association for Cancer Research (AACR). 2007 (Abstract).
3. Timothy TC Yip, William CS Cho, Roger KC Ngan, Tai-Tung Yip, Wai Wai Cheng, Victor WS Ma & Stephen CK Law. Oncoproteomics analysis of cancer associated serum peptides – problems & opportunities. Proceedings of the Fifth Chinese National Human Proteome Symposium (CNHUPO) 2007; (Abstract).
4. Timothy TC Yip, William CS Cho, Roger KC Ngan, Tai-Tung Yip, Wai Wai Cheng, Victor WS Ma & Stephen CK Law. Oncoproteomics analysis of cancer associated serum peptides – problems & opportunities. Proceedings of the Annual Symposium of Hong Kong Proteomics Society and Satellite Meeting of CNHUPO 2007. (Abstract).
5. William C.S. Cho, Timothy T.C. Yip, Roger K.C. Ngan, Tai-Tung Yip, Christine Yip, Harry H.Y. Yiu, Wai-Wai Cheng, Victor W.S. Ma, Stephen C.K. Law. Serum proteinchip profiling provides response prediction for nasopharyngeal carcinoma before and after chemotherapy. Proceedings of the Annual Meeting of the American Association for Cancer Research (AACR) 2008 (Abstract).
6. Timothy TC Yip, Roger KC Ngan, Stephen CK Law. Epstein-Barr virus & Nasopharyngeal Cancer - Roles of the viral genes/antigens in diagnosis, relapse monitoring & treatment. Proceedings of the National Infectious Disease Conference and 4th CAACM Clinical Microbiology Symposium. September 2008 (Abstract).
7. Timothy TC Yip, Roger KC Ngan,, Stephen CK Law. Cancer diagnosis, drug response study and inflammation analysis by serum proteomic profiling. Proceedings of the Annual Symposium of Hong Kong Proteomics Society November 2008 (Abstract).

FUNDRAISING AND PUBLICITY 籌募及推廣

The committee has devoted efforts in 2 major areas: (i) promoting the works of the Society, including brand-building, promotion of the Jockey Club Cancer Rehabilitation Centre and (ii) raising funds for supporting all areas of works of the Society including various assistance programs and public education programs.

Through different activities and events with tremendous support from experts and volunteers, we enlist the community's help so that cancer patients and their families can continue to lead a meaningful life with quality.

籌款及宣傳委員會致力於兩大範疇宣傳防癌會的工作，(i)包括品牌設計、賽馬會癌症康復中心宣傳等等，(ii)為本會籌募經費以資助本會所有活動，包括各項大眾援助計劃及公眾教育活動。

透過專業人士及義工朋友的幫助，我們舉辦了不同類型的活動及計劃，讓癌症患者及其家人獲得支援及關懷，繼續享受豐盛的人生。

Members of the Fundraising Subcommittee 2007/08 2007/08 年度籌募及推廣委員會委員名單

Chairperson 主席:	Mrs. Chu Yeung Pak-yu Patricia, BBS	朱楊珀瑜女士, BBS
Members 委員:	Mr. Edwin Chiu Ngar-wing Dr. Philip Fung Dr. Ko Wing-man Mr. Law Chi-keung Miss Connie Lam Dr. Pamela Leung Mrs. Selina Lo Ms. Alisha Ma Hsiao-hung Dr. Poon Yeuk-foo Dr. Wang Ming-chun Elizabeth, SBS Ms. Bonnie M.W. Wu	趙雅穎先生 馮炳全博士 高永文醫生 羅志強先生 林婉雯女士 梁明娟醫生 羅黃少眉女士 馬奕彤女士 潘若芙醫生 汪明荃博士, SBS 胡敏慧女士
Secretary 秘書:	Ms. Iris Leung	梁小雲小姐

MAJOR FUNDRAISING ACTIVITIES DURING THE PERIOD FROM 1 October 2007 to 30 September 2008 由2007年10月1日至2008年9月30日期間所舉辦的主要籌募活動

1 Island Scout Trail Walk cum Walk for Life 2008 港島童軍毅行暨活力行2008

Following the great success of the first Island Scout Trail Walk cum Walk for Life last year, the Society Co-organized the same event in 2008 with the Scout Association of Hong Kong HK Island Region and the Rotary Club of Hong Kong Harbour, with the aimed at raising funds for our “Prof. H.C. Ho Memorial Medical Assistance Program” which provides financial assistance and/or drug sponsorship to cancer patients who are unable to afford the recommended drugs listed as Self-Financed Items in the Hospital Authority Drug Formulary.

The event was held on a warm fine Sunday, 30 March 2008. More than 2,300 participants took part in the event and they were free to choose from the three trails of 8kms, 25kms or 50kms. Despite different starting-points and starting-times, all routes led to the finish-point at the Peak. In the closing ceremony, we had the great honour to have Mr. Anthony Wu, Chairman of Hospital Authority and Mr. Paul Tang, Permanent Secretary for Labour and Welfare as the Guests of Honour to give speech and to bestow awards and souvenirs to participants and sponsors.

We were most grateful to the unfailing support of the Scout Association of Hong Kong HK Island Region and the Rotary Club of Hong Kong Harbour, both had contributed to the great success of the event and raised over 1.3 million for the Society. Besides the fund raised “Island Scout Trail Walk cum Walk for Life 2008” had also successfully aroused public’s concern of cancer sufferers with financial difficulties.

承接去年成功舉辦慈善步行活動，今年，本會與香港童軍總會港島地域及香港海港扶輪社繼續合辦「港島童軍毅行暨活力行2008」慈善步行活動為「何鴻超教授紀念助醫計劃」籌募經費，助醫計劃提供經濟及/或藥物資助，協助癌症病人購買醫院管理局藥物名冊以外的自費癌症藥物。

慈善步行活動於2008年3月30日一個天色晴朗的星期天舉行，超過2,300名參與者，而步行路線分別有8公里、25公里及50公里，步行者可自由選擇合適的路線，由不同起點出發，前往山頂的終點完成整個行程。於結幕禮上，醫院管理局主席胡定旭先生及勞工及福利局常任秘書長鄧國威先生擔任主禮嘉賓，他們除了於典禮上致辭外，還頒贈紀念品給予參與者及贊助人。

是次活動得到香港童軍總會港島地域及香港海港扶輪社的鼎力支持和協助，得到美滿的成績，共籌得超過130萬元，為此本委員會特別向上述兩間機構致謝。除此之外，更重要的是透過「港島童軍毅行暨活力行2008」，令更多公眾人士關注貧困癌患者的需要。



2 Si Yuan Foundation Chinese Music Charity Concert 思源基金會慈善中樂演奏會

Jointly organized by Nanjing University and the Society, the Charity Concert was made possible at the Auditorium of Sha Tin Town Hall by the generous sponsorship of the Si Yuan Foundation on The Mother's Day, 11 May, 2008. We were honoured to have Dr. and Mrs. Chen Tseng-tao, Founders of Si Yuan Foundation, Professor Hong Yinxing, Vice President of Nanjing University, Ms. Laura Chen, Chair of ZeShan (H.K.) Foundation and The Hon. Rita FAN HSU Lai-tai, President of Legislative Council as the Guests of Honour to officiate the programme.

The Concert raised over HK\$2.4 million donation with the aimed at raising seed funds for the Jockey Club Cancer Rehabilitation Centre of our Society. Principal performers were drawn from Nanjing University's Traditional Instrument Orchestra, guest performers were Ms. Cheung Pui-lan, Alice, Mr. Tse Chun-yan and Mr. Sou Si-tai. The splendid performance left all the 1,300 audiences deeply impressed by a memorable evening.

本會很榮幸得到思源基金會的鼎力贊助，於2008年5月11日母親節與南京大學民族樂團假沙田大會堂合辦慈善中樂演奏會，感謝思源基金會創辦人陳曾燾伉儷、南京大學校務委員會主任洪銀興教授、擇善基金主席陳樂怡女士及立法會主席范徐麗泰議員擔任主禮嘉賓。

是次演奏會目的為香港防癌會賽馬會癌症康復中心籌募營運經費，合共籌得超過二百三十多萬元。主要的表演嘉賓來自南京大學中樂團，此外，本會亦邀請到張佩蘭女士、謝俊仁先生及蘇思棣先生參與演出，令超過1,300名善長渡過一個難忘晚上。



Acknowledgement 鳴謝

Donors of HK\$10,000 or more 1 October 2007 – 30 September 2008
2007年10月1日至2008年9月30日捐款港幣10,000元或以上的善長

Donors:	善長:	Amount (HK\$) 金額(港幣)
The Hong Kong Jockey Club Charities Trust	香港賽馬會慈善信託基金	53,843,442.87
Mrs. Marie Wei Wun Ho and Mr. Shau Wai Lam	林何衛雲及林秀槐	1,000,000.00
Late Madam Tsui San	已故崔生女士	1,000,000.00
S K Yee Medical Foundation	余兆麒醫療基金	852,000.00
Community Chest Hong Kong	香港公益金	512,400.00
Chun Wo Charitable Foundation Ltd.	俊和慈善基金有限公司	300,000.00
Anonymous	無名氏	263,200.00
Mr. Ko Tak Yiu	高德耀先生	230,000.00
Mathews Marine Consultants Ltd.	—	204,895.00
Chan Dang Social Services Foundation Ltd.	陳登社會服務基金會	200,000.00
Anonymous	—	200,000.00
ZeShan Foundation	擇善基金	200,000.00
sanofi-aventis Hong Kong Ltd.	賽諾菲安萬特香港有限公司	170,000.00
In memory of the late Au Yuk May	—	166,601.80
Muifa Watch Co., Ltd.	梅花表有限公司	110,000.00
Dr. Chan Un Chan Ina	陳婉珍博士	100,000.00
Dr. Patrick S.W. Fong	—	100,000.00
The S.H. Ho Foundation Ltd.	何善衡慈善基金會	100,000.00
Si Yuan Foundation	思源基金會	100,000.00
In memory of the late Ms Jeanne Tjia	已故謝懿生女士	100,000.00
Wealth Bright Co. Ltd.	裕旺有限公司	100,000.00
Merck Sharp & Dohme (Asia) Ltd.	美國默沙東藥廠有限公司	76,737.00
Fong's Family Foundation	方潤華基金	51,000.00
Mr. Chan Iu Seng	陳耀星先生	50,000.00
Fong Shu Fook Tong Foundation	方樹福堂基金	50,000.00
Ms. Hung Diana Wan Ling	—	50,000.00
Mr. Hui Bon Hoa, Stephane Bing	黃元彬	50,000.00
Mr. Kevin S. Lam	林詩琪先生	50,000.00
Lee Woo Sing	—	50,000.00
Oriental Watch Co., Ltd.	東方表行有限公司	50,000.00
Mr. Shum Man Wai Steven	岑文偉先生	50,000.00
The Yuen Yuen Institute	圓玄學院	50,000.00
Zhilan Foundation	芝蘭基金會	50,000.00
Pfizer Corporation Hong Kong Ltd.	美國輝瑞科研製藥	40,700.00
Rockreef Investment	—	40,000.00

Donors:	善長:	Amount (HK\$) 金額(港幣)
Holy Cross Church	聖十字架天主堂	34,852.00
Fung Yiu King Charitable Foundation Ltd.	馮堯敬慈善基金會	30,000.00
Mr. Mak Shiu Kin Michael	麥紹堅先生	30,000.00
Ocean Partners UK Ltd.	—	23,331.00
Team Bright Corporation Ltd.	—	22,210.00
Care & Health Ltd.	康而健有限公司	20,000.00
Caridad Ltd.	—	20,000.00
Mr. & Mrs. Chan Ping Wah	—	20,000.00
Chow Sang Sang Jewellery Co. Ltd.	周生生珠寶有限公司	20,000.00
Mrs. Luk Ho Mi Chun	—	20,000.00
Mrs. Mak Man Yuk Patty	麥蔡文玉女士	20,000.00
Wai Hung Charitable Foundation Ltd.	慧洪慈善基金有限公司	20,000.00
Ms. Wong Wai Yee	—	20,000.00
SOL Ltd.	—	17,500.00
Anonymous	無名氏	16,000.00
The Incorporated Trustees of the Zoroastrian Charity	波斯火教慈善基金	16,000.00
Mr. Luk Chi Cheong	—	15,000.00
Wai Tak Land Investment & Loan Co, Ltd.	懷德置業按揭有限公司	15,000.00
Mr. Tam Shiu Wah	譚紹華先生	12,000.00
Abbott Laboratories Ltd.	美國雅培製藥有限公司	10,000.00
Anonymous	無名氏	10,000.00
Anonymous	無名氏	10,000.00
Arjo Far East Ltd.	瑞典而久遠東有限公司	10,000.00
Bayer Schering Pharma	拜耳先靈醫藥	10,000.00
Mr. Roger Butt	—	10,000.00
Ms. Cheung Pui Lan Alice	張佩蘭女士	10,000.00
Mrs. Choi Ma Oi Kuen	蔡馬愛娟女士	10,000.00
Mr. Chong Claude Yuk Leung & Mrs. Chong Ada Irene	—	10,000.00
Mrs. Chu Leung Wai Chung Monica	朱梁慧中女士	10,000.00
Ms. Wong Fung Yuk Tong Agnes	黃馮玉棠女士	10,000.00
Dr. Dan Bing Kwan Robert	—	10,000.00
Dr. Doo King Sing David	杜景成醫生	10,000.00
Eli Lilly Asia, Inc.	美國禮來公司	10,000.00
GlaxoSmithKline Ltd.	葛蘭素史克有限公司	10,000.00
Hong Kong Communications Equipment Co., Ltd.	香港通訊器材有限公司	10,000.00
Mr. Hong Tse Keung	—	10,000.00

Donors:	善長:	Amount (HK\$) 金額(港幣)
Kennedy Burkill & Sons (HK) Ltd.	—	10,000.00
Mr. Kong Wing On	江永安先生	10,000.00
L & T Charitable Foundation Ltd.	慧賢慈善基金有限公司	10,000.00
Mr. Lai Ying Kam	黎應錦先生	10,000.00
Ms. Felicia Yik Ting Law	羅翊婷女士	10,000.00
Linson Company Ltd.	年新有限公司	10,000.00
Mr. Lee Kin Fai Andrew	李健輝先生	10,000.00
Mr. Lee Ming Fai Clarence	李明輝先生	10,000.00
Ms. Pei Shek Leun	費石鸞女士	10,000.00
Pacific Medical (HK) Co. Ltd.	帕斯醫材香港有限公司	10,000.00
Prince Jewellery and Watch Company	太子珠寶鐘錶公司	10,000.00
Mr. Rusy M Shroff & Mrs. Purviz R Shroff	—	10,000.00
Squina International Group Ltd.	雪肌蘭國際集團有限公司	10,000.00
Sum Mei Entertainment Production Ltd.	心美娛樂製作有限公司	10,000.00
Mr. Tong Chi Chung	—	10,000.00
Wei Lun Foundation Ltd.	偉倫基金有限公司	10,000.00

We are also grateful to our Hon. Auditors, Chang Leung Hui & Li C.P.A. Limited for auditing our accounts; our Hon. Legal Adviser, Mr. Steven Shum Man Kwong; the Community Chest of Hong Kong; the Hospital Authority and the various welfare agencies for their contribution, co-operation and helpful advice from time to time.

During the past year, my colleagues in the Committee and Subcommittees have been very supportive and constructive in assisting me in discharging my duties. I wish to thank each and everyone of them from the bottom of my heart for their valuable assistance, co-operation, and counsel. I also wish to thank the voluntary workers for their selfless contribution in making the patients' lives much more pleasant. Last but not least, I would like to thank the Society's staff for their loyalty and dedication.

我們非常感謝義務核數師張梁許李會計師事務所有限公司為本會核數、本會名譽法律顧問岑文光先生、香港公益金、醫院管理局和各福利團體的參與、合作及經常提出有益的建議。

過去一年，我得到執行委員會和各委員會同僚的大力支持和熱誠協助處理會務。本人在此衷心感謝他們寶貴的幫助和意見。我亦藉此機會多謝所有義工為了使癌症病人活得更好的無私奉獻。最後，我要多謝本會職員的忠誠和熱誠的工作。



Ko Wing Man 高永文

Chairman

The Hong Kong Anti-Cancer Society

香港防癌會主席

THE HONG KONG ANTI-CANCER SOCIETY
REPORT OF THE HONORARY TREASURER
FOR THE YEAR ENDED
31st MARCH, 2008

香港防癌會
義務司庫報告
截至2008年3月31日年度

THE HONG KONG ANTI-CANCER SOCIETY 香港防癌會

REPORT OF THE HONORARY TREASURER 義務司庫報告
FOR THE YEAR ENDED 31 MARCH 2008 截至2008年3月31日年度

During the year the Society had received donations and grant from the Hong Kong Jockey Club Charities Trust, the Community Chest of Hong Kong, our members and the general public totaling \$59.93M. The major outgoings were: \$48.48M for the Hong Kong Anti-Cancer Society Jockey Club Cancer Rehabilitation Centre project; \$3.52M for the betterment and medical assistance for cancer patients; \$1.32M for Cancer Education; \$0.54M for supporting Cancer Research; \$0.45M for Recreational & Diversional Therapy Unit; \$2.07M for general administration, and \$0.43M for other special purposes (Volunteers' Fund etc); totaling \$56.81M. Together with interest received and sundry income of \$1.20M, the net cash funds of the Society have increased about \$4.32M.

本年度本會合共獲得由香港賽馬會慈善信託基金、香港公益金、本會會員及大眾的撥款及慷慨捐贈總額為五千九百九十三萬元。該款項其中的四千八百四十八萬元用於香港防癌會賽馬會癌症康復中心，三百五十二萬元用於資助癌症病人改善生活及藥物；一百三十二萬元支付癌症教育；五十四萬用於資助癌症研究；四十五萬元用於康樂治療小組；而本會的行政開支佔二百零七萬元及其他基金(例如義工基金等)的雜費開支共四十三餘萬元；上述合共支出五千六百八十一餘萬元。連同利息及其他收入約一百二十萬元，在這年度內本會共增加了約四百三十二萬元的淨現金。

 趙雅穎

Edwin Chiu Ngar-wing 趙雅穎
Honorary Treasurer 義務司庫

Hong Kong, 8 December 2008
香港，2008年12月8日

THE HONG KONG ANTI-CANCER SOCIETY

(Incorporated in Hong Kong and limited by guarantee)

REPORTS AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED

31st MARCH, 2008

香港防癌會

(根據《香港公司條例》註冊成立之擔保有限公司)

全年截至2008年3月31日止

核數師報告

EXECUTIVE COMMITTEE'S REPORT 執行委員會之匯報

The members of the Executive Committee present their annual report together with the audited financial statements of the Society for the year ended 31st March, 2008.

執行委員會各委員現呈交截至2008年3月31日年度本會之週年匯報及經審核之財務報表。

Principal activity 主要活動

The Society continues to undertake activities against cancers.

本會繼續推行對抗癌症活動。

Results 賬目

The results of the Society for the year ended 31st March, 2008 are set out in the Society's Administration Fund income and expenditure account on page 62.

本會截至2008年3月31日年度之賬目詳情編載於第62頁的收入與支出明細表內。

Property, plant and equipment 物業、設備及器材

Movements in property, plant and equipment during the year are shown in note 3 to the financial statements.

本年度物業、設備及器材之變動編載於財政報告賬項註釋三中。

Executive Committee 執行委員會

The following are current members of the Executive Committee, having served throughout the year, except as indicated:

隨特別標明外，下列為現任執行委員會委員，於本年度均圓滿服務一年：

Chairman 主席:	Dr. Ko Wing Man	高永文醫生
Vice-Chairman 副主席:	Dr. Poon Yeuk Foo	潘若芙醫生
Honorary Secretary 義務秘書:	Mr. Davie Au-Yeung Tsan Pong	歐陽贊邦先生
Honorary Treasurer 義務司庫:	Mr. Edwin Chiu Ngar Wing	趙雅穎先生
	Mrs. Chu Yeung Pak Yu, Patricia, B.B.S.	朱楊珀瑜女士，B.B.S.
	Dr. Daniel Chua Tsin Tien	蔡清鴻醫生
	Dr. Law Chun Key	羅振基醫生
	Dr. Anne Lee Wing Mui	李詠梅醫生
	Dr. Pamela Leung	梁明娟醫生
	Mrs. Selina Lo	羅黃少眉女士
	Ms. Alisha Ma	馬奕彤女士
	Dr. Tung Yuk	董煜醫生
	Dr. Elizabeth Wang Ming Chun, S.B.S.	汪明荃女士，S.B.S.
	Mrs. Agnes Wong	黃馮玉棠女士
	Dr. Anthony Ying Chi Ho	應志浩醫生
	Dr. Hubert Chan	陳重義博士
	Mr. John Wong	黃培傑先生
	Mr. Shum Man Kwong	岑文光先生

(appointed on 7th December 2007)
(2007年12月7日獲委任)

(appointed on 7th December 2007)
(2007年12月7日獲委任)

(retired on 7th December 2007)
(2007年12月7日任期圓滿)

EXECUTIVE COMMITTEE'S REPORT 執行委員會之匯報

In accordance with Article 53 of the Society's Articles of Association, the current members of the Executive Committee will retire at the forthcoming annual general meeting and, being eligible, offer themselves for re-election.

根據本會公司章程第53節，現任執行委員會成員將在來屆週年大會任期完滿，如適任者，可續選為委員。

Executive Committee's interests in contracts 執行委員會之合約權益

No contract of significance, to which the Society and members of the Executive Committee had a material interest, whether directly or indirectly, subsisted at the end of the year or at any time during the year.

於年終時及在這年度內，並無存在有直接或間接的致使本會及執行委員會成員可享有關益的重大合約。

Auditors 核數師

The financial statements have been audited by Messrs. Chang Leung Hui & Li C.P.A. Limited, Certified Public Accountants, who retire and being eligible, offer themselves for re-appointment.

本財務報表由張梁許李會計師事務所有限公司審核，並委任期滿，如適任者，可再獲委任。

On behalf of the Executive Committee
承執行委員會命



Chairman 主席

HONG KONG, 25TH SEPTEMBER, 2008
香港，2008年9月25日

INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF THE HONG KONG ANTI-CANCER SOCIETY

(Incorporated in Hong Kong and limited by guarantee)

致香港防癌會各會員獨立核數師報告

(以擔保形式於香港註冊成立的有限公司)

We have audited the financial statements of The Hong Kong Anti-Cancer Society set out on pages 61 to 73, which comprise the balance sheet as at 31st March, 2008, and the income and expenditure account, statement of changes in accumulated funds and cash flow statement for the year then ended, and a summary of significant accounting policies and other explanatory notes.

本核數師已完成審計香港防癌會刊於第61頁至第73頁包括截至2008年3月31日之資產負債；本年度的收入與支出、累積基金的變動及現金流量等賬目與及主要會計政策及其他賬項註釋的總結。

Executive Committee's responsibility for the financial statements

執行委員會對這財務報表的責任

The Executive Committee are responsible for the preparation and the true and fair presentation of these financial statements in accordance with Hong Kong Financial Reporting Standards issued by the Hong Kong Institute of Certified Public Accountants and the Hong Kong Companies Ordinance. This responsibility includes designing, implementing and maintaining internal control relevant to the preparation and the true and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

執行委員會須負責按照由香港會計師公會頒布的《香港財務報告準則》及《香港公司條例》之披露規定編製真實與公平的財務報表。這責任包括設計、執行和維持相關的內部監控以編製真實與公平的財務報表，不會因欺騙或失誤而導至錯誤陳述；選擇和應用合適的會計政策；並在相關的情況下作出合理的賬項估值。

Auditors' responsibility 核數師對這財務報表的責任

Our responsibility is to express an opinion on these financial statements based on our audit. This report is made solely to you, as a body, in accordance with Section 141 of the Hong Kong Companies Ordinance, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

本核數師的責任是根據我們的審計工作結果對這財務報表發表意見。按照《香港公司條例》141條，僅向香港防癌會會員報告；除此之外，本財務報表別無其他目的。本核數師不會就本財務報表的內容向任何其他人士負上或承擔任何責任。

We conducted our audit in accordance with Hong Kong Standards on Auditing issued by the Hong Kong Institute of Certified Public Accountants. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance as to whether the financial statements are free from material misstatement.

本核數師已按照香港會計師公會頒布的《香港核數準則》進行審計工作。這些準則要求我們遵從一貫道德標準以計劃及執行審計工作，就該等財務報表有否存有錯誤陳述獲得合理的保證。

**INDEPENDENT AUDITORS' REPORT
TO THE MEMBERS OF THE HONG KONG ANTI-CANCER SOCIETY
(Incorporated in Hong Kong and limited by guarantee)
致香港防癌會各會員獨立核數師報告
(以擔保形式於香港註冊成立的有限公司)**

Auditors' responsibility 核數師對這財務報表的責任 (continued續前頁)

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the entity's preparation and true and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Executive Committee, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion 意見

In our opinion, the financial statements give a true and fair view of the state of the Society's affairs as at 31st March, 2008 and of its results and cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards and have been properly prepared in accordance with the Hong Kong Companies Ordinance.

審計的工作著重於執程序，以取得這財務報表裡有關的數額和披露的會計實證。程序的選擇取決於本核數師的判斷，包括有否因欺騙或失誤而導至錯誤陳述的風險作出評估。在進行這些風險評估時，本核數師會考慮其相應的內部監控以編製個別真實與公平的財務報表，配合當時情況構思合適的審計序程，而不會對個別內部監控的有效性而發表獨立意見。審計工作還包括評估會計政策的恰當情度，執行委員會對會計上採用的估計是否合理和整體財務報表的編製。

我們相信，我們所獲得的審計實證已充份地和適當地為我們的審計意見提供依據。

本核數師認為，根據《香港財務報告準則》，上述的財務報表真實而公平地反映貴會於2008年3月31日的財政狀況及貴會截至該年度終結日的賬目與現金流量，並已按照《香港公司條例》適當編製。



CHANG LEUNG HUI & LI C.P.A. LIMITE
Certified Public Accountants
香港執業會計師
張梁許李會計師事務所有限公司

Edmond Chi Kong Leung
Practising Certificate Number P1353
梁梓綱會計師執業牌照碼P1353

**HONG KONG, 25TH SEPTEMBER, 2008
香港，2008年9月25日**

BALANCE SHEET AS AT 31ST MARCH, 2008
全年截至2008年3月31日止資產負債表

			2008	2007
		Note	HK\$	HK\$
		註釋	港幣	港幣
Non-current assets	非流動資產			
Property, plant and equipment	物業、設備及器材	3	61,236,164	17,202,810
Current assets	流動資產			
Other receivables	其他應收賬		5,500	5,500
Bank balances and cash	銀行結餘及現金	4	33,844,538	29,527,166
			<u>33,850,038</u>	<u>29,532,666</u>
Net assets	資產淨值		<u>95,086,202</u>	<u>46,735,476</u>
Financed by :	基金：			
Capital control account	資本統制賬	5	61,236,164	17,202,810
Society's administration fund	會務行政基金		-	261,618
Funds received for special purposes	特別基金	6	31,103,056	27,531,500
General reserve fund	普通儲備	7	2,746,982	1,739,548
Approved and authorised for issue by the Executive Committee on 25th September 2008	2008年9月25日由 執行委員會 通過及授權簽署：			
				
Chairman 主席	Honorary Treasurer 義務司庫		<u>95,086,202</u>	<u>46,735,476</u>

SOCIETY'S ADMINISTRATION FUND

INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31ST MARCH, 2008

全年截至2008年3月31日止會務行政基金收入與支出明細表

		Note	2008 HK\$ 港幣	2007 HK\$ 港幣
Income	收入			
Donations	捐款		10,500	140,000
Grant from the Community Chest of Hong Kong	香港公益金撥款		200,000	200,000
Membership subscriptions	會員會費		600	1,100
Other income	其他收入		47,600	23,700
Regrouping of Fund	基金重組		18,414	-
Interest received	利息收入		1,154,475	648,837
			<u>1,431,589</u>	<u>1,013,637</u>
Expenditure	支出			
Electricity	電費		-	16,236
Equipment	添置設備		10,079	-
Fuel and gas	燃油及汽體燃料		24,693	25,824
Incidental expenses	其他支出		580,520	299,939
Insurance	保險		15,717	14,371
Miscellaneous expenses	雜費		41,602	28,623
Printing and stationery	印刷及文具		149,108	50,201
Provident fund	強積金		57,796	10,000
Publication and advertisement	出版及廣告費		32,738	18,195
Repairs and maintenance	修理及保養		450	2,380
Salaries	薪金		1,061,966	192,839
Subscriptions and books	會費及訂閱費		27,574	41,415
Telephone and postage	電話及郵費		43,831	30,286
Travelling expenses	交通費用		25,176	21,629
Water	水費		-	81
			<u>2,071,250</u>	<u>752,019</u>
(Deficit)/Surplus for the year	本年(赤字)/盈餘		(639,661)	261,618
Balance brought forward	往年結餘		261,618	-
			(378,043)	261,618
Deficit absorbed by general reserve fund	由普通儲備承擔之赤字	7	378,043	-
Balance carried forward	本年結餘		<u>-</u>	<u>261,618</u>

**STATEMENT OF CHANGES IN ACCUMULATED FUNDS
FOR THE YEAR ENDED 31ST MARCH, 2008**
全年截至2008年3月31日止基金變動表

		Capital control account 資本 統制賬	Funds received for special purposes 特別基金	General reserve fund 普通儲備	Society's admini- stration fund 會務行政基金	Total 合計
		HK\$ 港幣 (Note註釋5)	HK\$ 港幣 (Note註釋6)	HK\$ 港幣 (Note註釋7)	HK\$ 港幣	HK\$ 港幣
Balance at 1st April, 2006	1.4.2006 結餘	17,513,165	23,779,936	1,438,886	-	42,731,987
Surplus for the year	本年盈餘	-	-	-	261,618	261,618
Transfer	基金轉撥	-	819,906	(819,906)	-	-
Increase during the year	本年度增加	276,019	18,945,447	1,120,568	-	20,342,034
Decrease during the year	本年度減少	(586,374)	(16,013,789)	-	-	(16,600,163)
Balance at 1st April, 2007	1.4.2007 結餘	17,202,810	27,531,500	1,739,548	261,618	46,735,476
Deficit for the year	本年赤字	-	-	-	(639,661)	(639,661)
Transfer	基金轉撥	-	178,315	(556,358)	378,043	-
Increase during the year	本年度增加	49,904,730	58,365,960	1,354,977	-	109,625,667
Decrease during the year	本年度減少	(5,871,376)	(54,745,490)	-	-	(60,616,866)
Regrouping of funds	基金重組	-	(227,229)	208,815	-	(18,414)
Balance at 31st March, 2008	31.3.2008結餘	<u>61,236,164</u>	<u>31,103,056</u>	<u>2,746,982</u>	<u>-</u>	<u>95,086,202</u>

**CASH FLOW STATEMENT FOR
THE YEAR ENDED 31ST MARCH, 2008
全年截至2008年3月31日止現金流量表**

			2008	2007
		Note	HK\$	HK\$
		註釋	港幣	港幣
(Increase)/Decrease in :	(增加)/減少:			
Other receivables	其他應收賬			3,738,550
Increase/(Decrease) in :	(增加)/減少:			
Society's administration fund	會務行政基金		(261,618)	261,618
Funds received for special purposes	特別基金		3,571,556	3,751,564
General reserve fund	普通儲備		1,007,434	300,662
Increase in cash and cash equivalents	現金及現金等價物之增加		4,317,372	8,052,394
Cash and cash equivalents at beginning of the year	年初之現金及現金等價物		29,527,166	21,474,772
Cash and cash equivalents at end of the year	年末之現金及現金等價物		33,844,538	29,527,166
Analysis of the balances of cash and cash equivalents	現金及現金等價物結餘之分析			
Bank balances and cash	銀行結餘及現金		33,844,538	29,527,166

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2008 全年截至2008年3月31日止賬項註釋

1. Society information 本會資料

The Society is incorporated in Hong Kong and is limited by guarantee. It is a charitable body engaged in the undertaking of activities against cancers.

The registered office of the Society is located at 30 Nam Long Shan Road, Wong Chuk Hang, Hong Kong.

本會乃於香港以擔保形式註冊成立之有限公司。本會乃一慈善團體從事參與各項抗癌的活動。

本會註冊會址為香港黃竹坑南朗山道30號。

2. Principal accounting policies 主要會計策略

(a) Statement of compliance 遵照規定聲明

The financial statements have been prepared in accordance with all applicable Hong Kong Financial Reporting Standards ("HKFRSs") which term collectively include all applicable Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKAS") and Interpretations issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"), accounting principles generally accepted in Hong Kong ("HKGAAP") and the requirements of the Hong Kong Companies Ordinance.

本財務報表乃遵照香港會計師公會頒布所有適用的《香港財務報告準則》(其統稱已包括個別適用的《香港財務報告準則》、《香港會計準則》及詮釋)，香港普遍採納之會計原則及《香港公司條例》之披露規則編製。

(b) Basis of preparation 編製基準

The financial statements have been prepared under the historical cost basis.

The Society has not yet applied the new HKFRSs that have been issued but not yet effective for accounting periods beginning on or after 1st April, 2008. The Executive Committee anticipate that the adoption of these new HKFRSs will have no material impact on the financial statements.

本財務報表是按照歷史成本作為編製基準。

本會仍未採用已頒布但未生效適用於新的《香港財務報告準則》2008年4月1日開始之會計年度。執行委員會預期採納這些新的《香港財務報告準則》將不會對財務報表有實質影響。

(c) Revenue recognition 收入確認

Donations, grants and membership subscriptions are recognised when the amounts are received.

Interest income is accrued on a time basis, by reference to the principal outstanding and at the applicable interest rates.

捐贈、撥款及會員會費於收取同時的財政年度內已確認入賬。

銀行存款的利息收入以時間基準按結存金額和適用利率計算

2. Principal accounting policies 主要會計策略 (continued 接上頁)

(d) Property, plant and equipment 物業、設備及器材

Additions to property, plant and equipment are charged to the income and expenditure account of the respective funds when incurred. For the purpose of control, additions to property, plant and equipment are also recorded in capital control account and are carried in the balance sheet.

Fixed assets are stated in the balance sheet at cost less accumulated depreciation and impairment losses, if any.

Depreciation is calculated to write off the costs of assets less their estimated residual value, if any, on a straight-line basis over their estimated useful life as follows :

Buildings 物業	Over the remaining unexpired terms of the respective lease 各自租約的剩餘未到期期限
Furniture and equipment 傢俱設備	25%
Leasehold improvement 物業裝修	10%
Motor vehicles 汽車	25%

The residual value and the useful life of an item or a group of assets are reviewed at least annually at each financial year-end.

The Society assesses at each reporting date whether there is any indication that any items of property, plant and equipment may be impaired and that an impairment loss recognised in prior periods for an item may have decreased. If any such indication exists, the company estimates the recoverable amount of the item. An impairment loss, being the amount by which the carrying amount of an asset or a cash-generating unit exceeds its recoverable amount, or a reversal of impairment loss is recognised immediately in the capital control account.

Gain or loss arising from the derecognition of an item of property, plant and equipment is included in the capital control account when the item is derecognised and is determined as the difference between the net disposal proceeds, if any, and the carrying amount of the item.

物業、設備及器材的添置在各自有關基金的收支賬內刊載。為了方便統制，物業、設備及器材的添置在資本統制賬中亦有記錄及在資產負債表中載明。

固定資產均按其成本減去累積折舊和任何減值在資產負債表中列賬。

折舊之計算用以註銷資產的成本，故此物業、設備及器材根據其估計可使用年期減去任何剩餘價值後，以直線法按照下列比率攤銷：

每項或每組資產的剩餘價值及可使用年期均於每個結算日進行檢討。

於每個結算日，本會評估有否任何跡象顯示物業、設備及器材可能出現減值，先前確認那些減值虧損可能已減少。若有這些跡象顯示的存在，本會當估計這些資產的可收回價值。當一項資產或該資產所屬之現金產生單位之賬面值超過其可收回價值時，所得之減值虧損或撥回須於資本統制賬確認。。

每項物業、設備及器材因註銷確認而產生的盈餘或虧損，即註銷確認時所得任何的出售淨收入及賬面淨值的差額，已在資本統制賬中列賬。

(e) Taxation 稅項

The Society is a charitable body and is exempted from Hong Kong Taxation by virtue of Section 88 of the Inland Revenue Ordinance.

本會乃一慈善機構，根據《香港稅務條例》第八十八條可獲豁免香港稅項。

(f) Retirement benefit costs 退休保障成本

Payment to the defined contribution retirement benefit scheme are charged as an expense as they fall due.

既定供款退休保障計劃規定下應付的僱主供款均於應繳付日期被列作開支。

**NOTES TO FINANCIAL STATEMENTS FOR
THE YEAR ENDED 31ST MARCH, 2008**
全年截至2008年3月31日止賬項註釋

3. Property, plant and equipment 物業、設備及器材

	Land and buildings 土地及房屋	Motor vehicle 汽車	Furniture and equipment 傢俱設備	Leasehold improvement 物業裝修	Total 合計
	HK\$ 港幣	HK\$ 港幣	HK\$ 港幣	HK\$ 港幣	HK\$ 港幣
2008					
Cost 成本					
At 1.4.2007 結餘	18,006,121	1	300,431	-	18,306,553
Additions 增添	-	-	2,001,640	47,903,090	49,904,730
At 31.3.2008 結餘	18,006,121	1	2,302,071	47,903,090	68,211,283
Accumulated depreciation 累積折舊					
At 1.4.2007 結餘	1,016,816	-	86,927	-	1,103,743
Charge for the year 本年度開支	508,408	-	572,659	4,790,309	5,871,376
At 31.3.2008 結餘	1,525,224	-	659,586	4,790,309	6,975,119
Net book value 賬面淨值					
At 31.3.2008 結餘	16,480,897	1	1,642,485	43,112,781	61,236,164
2007					
Cost 成本					
At 1.4.2006 結餘	18,006,121	1	24,412	-	18,030,534
Additions 增添	-	-	276,019	-	276,019
At 31.3.2007 結餘	18,006,121	1	300,431	-	18,306,553
Accumulated depreciation 累積折舊					
At 1.4.2006 結餘	508,408	-	8,961	-	517,369
Charge for the year 本年度開支	508,408	-	77,966	-	586,374
At 31.3.2007 結餘	1,016,816	-	86,927	-	1,103,743
Net book value 賬面淨值					
At 31.3.2007 結餘	16,989,305	1	213,504	-	17,202,810

The land and buildings are situated in Hong Kong. The land is leased from the Hong Kong Special Administrative Region ("HKSAR") and can be terminated in twelve months' notice when the land is required by HKSAR for public purposes.

土地及房屋位於香港。土地租自香港特別行政區（“HKSAR”）及如因公共事務由香港特別行政區需用該地，可在12個月前通知終止租用。

NOTES TO FINANCIAL STATEMENTS FOR
THE YEAR ENDED 31ST MARCH, 2008
全年截至2008年3月31日止賬項註釋

4. Bank balances and cash 銀行結餘及現金

		2008	2007
		HK\$ 港幣	HK\$ 港幣
Fixed and call deposits	定期與通知存款	28,664,867	14,096,487
Savings accounts	儲蓄賬戶	3,623,141	9,625,755
Current accounts	往來賬戶	1,547,530	5,795,924
Petty cash	零用現金	9,000	9,000
		<u>33,844,538</u>	<u>29,527,166</u>

5. Capital control account 資本統制賬

		2008	2007
		HK\$ 港幣	HK\$ 港幣
Balance brought forward	往年結餘	17,202,810	17,513,165
Purchase of fixed assets	購買固定資產	49,904,730	276,019
Depreciation charge for the year	本年度折舊	(5,871,376)	(586,374)
		<u>61,236,164</u>	<u>17,202,810</u>
Balance carried forward	本年結餘		

6. Funds received for special purposes 特別基金

Movements of funds received for special purposes were as follows 收集作特別用途的基金運用如下:

Name of fund 基金名稱	Balance as at 1.4.2006 結餘	Fund transfer 基金轉撥	Income 收入	Expenditure 支出	Balance as at 1.4.2007 結餘	Re-grouping of funds 基金重組	Fund transfer 基金轉撥	Income 收入	Expenditure 支出	Balance as at 31.3.2008 結餘
Betterment Fund for Cancer Patients 「改善癌病人生活」基金	3,929,463	-	5,359,362	4,159,135	5,129,690	-	-	4,760,736	2,749,292	7,141,134
Building Redevelopment Fund 大樓重建基金	9,842,547	-	-	-	9,842,547	789,037	-	-	4,999	10,626,585
Cancer Detection and Prevention Fund 癌病探測及預防基金	1,741,348	-	7,000	45,000	1,703,348	-	-	9,600	7,817	1,705,131
Cancer Education Fund 癌症教育基金 (note註釋 8)	-	819,906	1,026,661	1,846,567	-	80,029	178,315	1,062,805	1,321,149	-
Cancer Hotline Fund 癌病熱線基金	82,888	-	-	2,859	80,029	(80,029)	-	-	-	-
Cancer Rehabilitation Centre Fund 癌症康復中心基金 (note註釋 10)	(521,061)	-	8,779,569	8,736,957	(478,449)	-	-	48,174,681	48,479,371	(783,139)
Cancer Rehabilitation Centre Development Fund 癌症康復中心發展基金	-	-	1,820,155	-	1,820,155	-	-	3,334,620	277,082	4,877,693
Cancer Research Fund 癌症研究基金	4,191,292	-	22,400	526,116	3,687,576	-	-	30,078	539,867	3,177,787
Purchase of Equipment Fund 購買醫院裝備基金	817,137	-	-	28,100	789,037	(789,037)	-	-	-	-
Recreational and Diversional Therapy Unit Fund 康樂治療基金 (note註釋 9)	118,738	-	511,400	448,030	182,108	-	-	482,240	454,116	210,232
Staff Education Fund 員工教育基金	20,864	-	-	2,450	18,414	(18,414)	-	-	-	-
Society's 40th Anniversary Fund 香港防癌會40週年基金	230,715	-	-	21,900	208,815	(208,815)	-	-	-	-
Special Hospice Care Fund 善終服務基金	3,320,131	-	18,900	133,575	3,205,456	-	-	11,200	136,582	3,080,074
Supportive Medical Assistance Programme 癌症病人慈惠助醫計劃	-	-	1,400,000	60,600	1,339,400	-	-	500,000	772,715	1,066,685
Volunteers' Fund 義工基金	5,874	-	-	2,500	3,374	-	-	-	2,500	874
	23,779,936	819,906	18,945,447	16,013,789	27,531,500	(227,229)	178,315	58,365,960	54,745,490	31,103,056

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2008 全年截至2008年3月31日止賬項註釋

6. Funds received for special purposes 特別基金(continued接上頁)

		2008	2007
		HK\$ 港幣	HK\$ 港幣
Donations	捐贈	8,559,815	7,998,504
Grants from the Community Chest of Hong Kong	香港公益金撥款	1,114,500	1,259,000
Grants from the Hong Kong Jockey Club Charities Trust	香港賽馬會慈善信託基金撥款	48,573,681	9,178,569
Others	其他	117,964	509,374
		<u>58,365,960</u>	<u>18,945,447</u>

No emoluments, pensions or compensation for loss of office were paid or any present or past members of the Executive Committee for both years.

過去及本年度均無支付任何酬金、退休金或離職補償金與現任或離任的執行委員會成員。

Total staff costs for the year amounting to HK\$3,855,938 (2007: HK\$3,155,599) were included in expenditure.

本年度職員成本已計算在支出賬項中，總數為港幣3,855,938元（2007年為：港幣3,155,599元）。

Included in the total staff costs, HK\$322,976 (2007: HK\$315,386) represents the contribution payable to the defined contribution retirement benefit schemes by the Society in respect of the current accounting year.

職員成本包括港幣322,976元（2007年為：港幣315,386元）為本會在本年度就既定供款退休保障計劃規定的應付僱主供款的總額。

7. General Reserve Fund 普通儲備

		2008	2007
		HK\$ 港幣	HK\$ 港幣
Balance brought forward	往年結餘	1,739,548	1,438,886
Regroup of fund from Society's 40th Anniversary Fund	來自香港防癌會40週年基金重組的基金	208,815	-
Fund transferred to Cancer Education Fund (Note 8)	轉入癌症教育基金(註釋 8)	(178,315)	(819,906)
Donations	捐款	1,354,977	915,898
Fund transferred to Society's Administration Fund	轉入會務行政基金	(378,043)	-
Other income received	其他收入	-	204,670
Balance carried forward	本年結餘	<u>2,746,982</u>	<u>1,739,548</u>

**NOTES TO FINANCIAL STATEMENTS FOR
THE YEAR ENDED 31ST MARCH, 2008**
全年截至2008年3月31日止賬項註釋

8. Cancer Education Fund 癌症教育基金

		2008	2007
		HK\$	HK\$
		港幣	港幣
Balance brought forward	往年結餘	-	-
Regrouping of fund	基金重組	80,029	-
		<u>80,029</u>	<u>-</u>
Income :	收入 :		
Donations	捐款	302,841	114,793
Other income	其他收入	111,618	101,203
Grant from the Community Chest of Hong Kong	香港公益金撥款	642,000	809,000
Receipt of royalty fee	新書版稅收益	1,028	607
Sale of cancer books	銷售癌症新書收益	5,318	1,058
		<u>1,062,805</u>	<u>1,026,661</u>
Expenditure :	支出 :		
Cancer course and seminars	課程費用	2,850	16,320
Equipment	添置設備	450	-
Incidental expenses	其他支出	130,732	21,567
Insurance	保險	5,717	8,402
Miscellaneous expenses	雜費	5,548	46,327
Printing and stationery	印刷及文具	18,640	45,884
Provident fund	公積金	106,588	195,732
Publication and advertisement	出版及廣告費	165,126	65,800
Repairs and Maintenance	維修及保養	2,100	-
Salaries	薪金	869,407	1,435,400
Telephone and postage	電話及郵費	9,418	10,040
Travelling expenses	交通費用	4,573	1,095
		<u>1,321,149</u>	<u>1,846,567</u>
Fund transferred from General Reserve Fund (Note 7)	普通儲備轉撥 (註釋7)	178,315	819,906
		<u>-</u>	<u>-</u>
Balance carried forward	本年結餘	<u>-</u>	<u>-</u>

NOTES TO FINANCIAL STATEMENTS FOR
THE YEAR ENDED 31ST MARCH, 2008
全年截至2008年3月31日止賬項註釋

9. Recreational and Diversional Therapy Unit Fund 康樂治療基金

		2008	2007
		HK\$ 港幣	HK\$ 港幣
Balance brought forward	往年結餘	182,108	118,738
Income :	收入 :		
Donations	捐款	9,740	61,400
Grant from the Community Chest of Hong Kong	香港公益金撥款	472,500	450,000
		482,240	511,400
Expenditure :	支出 :		
Incidental expenses	其他支出	-	94
Insurance	保險	1,624	2,112
Miscellaneous expenses	雜費	76	6,499
Printing and stationery	印刷及文具	1,462	1,400
Program expenses	節目支出	24,921	20,633
Provident fund	公積金	47,986	49,854
Salaries	薪金	371,310	360,240
Telephone and postage	電話及郵費	2,503	3,258
Travelling expenses	交通費用	4,234	3,940
		454,116	448,030
Balance carried forward	本年結餘	210,232	182,108

NOTES TO FINANCIAL STATEMENTS FOR
THE YEAR ENDED 31ST MARCH, 2008
全年截至2008年3月31日止賬項註釋

10. Cancer Rehabilitation Centre Fund 癌症康復中心基金

		2008	2007
		HK\$ 港幣	HK\$ 港幣
Balance brought forward	往年結餘	(478,449)	(521,061)
Income :	收入 :		
Donations from The Hong Kong Jockey Club Charities Trust	香港賽馬會慈善信託基金的捐贈	48,174,681	8,779,569
Less : Expenditure	減:支出		
Construction work	建築工程	43,565,090	4,338,000
Consultancy fees	工程顧問費	1,255,742	2,479,000
Equipments	添置設備	1,725,028	247,868
Furniture and fixtures	傢俱及裝置	15,360	-
Incidental expenses	其他支出	28,326	249,117
Insurance	保險	19,907	14,802
Miscellaneous expenses	雜費	14,016	147,800
Printing and stationery	印刷及文具	43,847	23,806
Provident fund	公積金	95,911	45,400
Rent and rates	差餉及地稅	296,447	257,922
Repairs and maintenance	修理及保養	-	91,094
Salaries	薪金	1,413,662	714,934
Telephone and postage	電話及郵費	4,960	3,340
Utilities	公共開支	1,075	123,874
		48,479,371	8,736,957
Balance carried forward	本年結餘	(783,139)	(478,449)

DESCRIPTION OF THE USAGE OF FUNDS FOR THE YEAR ENDED 31ST MARCH, 2008 全年截至2008年3月31日止賬項註釋

Name of fund 基金名稱	Usage of fund 基金用途
Building Redevelopment Fund 大樓重建基金	For Nam Long Hospital extension projects 用於南朗醫院擴展計劃
Betterment Fund for Cancer Patients 「改善癌病人生活」基金	To provide financial assistance to cancer patients 用於提供給癌症病人的財政資助
Cancer Detection and Prevention Fund 癌病探測及預防基金	To be used for cancer detection and prevention projects 用於癌病探測及預防計劃
Cancer Education Fund 癌症教育基金	To meet operating costs for cancer education activities 用於支付癌症教育活動的經營成本
Cancer Research Fund 癌病研究基金	To be used for cancer research projects and related expenses 用於支付癌症研究計劃及相關的支出
Recreational and Diversional Therapy Unit Fund 康樂治療基金	To meet operating costs for running the Recreational and Diversional Therapy Unit 用於支付康樂治療小組的經營成本
Special Hospice Care Fund 善終服務基金	To meet the running costs of hospice care service 用於支付善終服務的運作成本
Volunteers' Fund 義工基金	To meet operating costs for running volunteers' program 用於支付義工計劃的經營成本
Cancer Rehabilitation Centre Fund donated by The Hong Kong Jockey Club Charities Trust 癌症康復中心基金 (由香港賽馬會慈善信託基金捐贈)	To meet the project costs of the establishment of the Cancer Rehabilitation Centre. 用於設立癌症康復中心計劃的開支
Cancer Rehabilitation Centre Development Fund 癌症康復中心發展基金	To meet the development and running costs of the Cancer Rehabilitation Centre 用以支付癌症康復中心運作開支及發展之用
General Reserve Fund 普通儲備	To meet the deficits of funds 用於彌補會務行政基金及康樂治療基金的赤字
Supportive Medical Assistance Programme 癌症病人慈惠助醫計劃	To provide financial assistance to cancer patients in accordance with specific criteria 根據特別準則為癌症病人提財政資助

註： 本中文版本乃根據英文版本原文翻譯，若有任何文字上的矛盾，則以英文版本為準。

「何鴻超教授紀念助醫計劃」

你們的捐助
燃亮了我們
生命得延續
感激無限!!!
祝願大家健康愉快

贈醫施藥
感恩無限

謝謝香港防癌會在我
們一家處於徬徨及黑暗的期
間伸出援手，讓我們能重見光
明，萬分感激!!

非常感謝「何鴻超教授紀念計
劃」基金以及所有熱心人士令經濟有
困難的病人有機會接受良好的
治療，令很多病人得益及康復。

受惠人
感謝點滴

本人是家庭經濟支柱，但因患癌症而不能工
作，又要支付昂貴的醫藥費。現向“香港防癌會”
申請經濟困難的癌症病人購買需自費的化療
藥物的藥費獲得撥款，舒緩一紙困難。我們
全家感激萬分。謝謝!

為保障個人私隱，
受惠人之姓名不予刊登。

香港黃竹坑南朗山道三十號

30 Nam Long Shan Road, Wong Chuk Hang, Hong Kong

查詢 Enquiry: 3921 3821 網址 Website: www.hkacs.org.hk